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61. Abstract
Entacapone and tolcapone are novel
catechol-O-methyltransferase (COMT)
inhibitors developed for adjunctive
treatment with levodopa in Parkinson’s
disease (PD). In clinical use, tolcapone has
induced severe hepatic dysfunction,
including three fatal cases. Tolcapone, but
not entacapone, has also been shown to be
an uncoupler of oxidative phosphorylation
in vitro at low micromolar concentrations.
The toxicity of entacapone and tolcapone
was compared in animal studies in vivo and
in vitro. 2,4-dinitrophenol (DNP), a known
uncoupling agent, was used as a reference
substance. In the in vivo studies, rats were
treated with high repeated oral doses.
Clinical symptoms, mortality and rectal
body temperature were recorded. Further-
more, clinical chemistry and haematological
parameters were measured, and at necropsy,
tissue samples for histological examination
and biochemical determinations were
extracted. At cellular level, mitochondrial
energy status was determined after oral
treatment in rats. In vitro, mitochondrial
membrane potential in isolated rat liver
mitochondria was determined to obtain
data on the direct effects of these agents on
uncoupling of oxidative phosphorylation.
To evaluate the role of total COMT
inhibition in the toxicity of COMT
inhibitors, mice lacking the Comt -gene were
used to assess COMT inhibition-induced
pathology in organs expressing high
COMT activity in otherwise healthy
animals.
Entacapone was well tolerated at high
oral repeated doses by rats. Tolcapone
induced clinical signs and increased
mortality at liver concentrations that caused
no adverse effects with entacapone. Rectal
body temperature increased with tolcapone
and DNP treatments. Rigor mortis
occurred instantly after death in tolcapone-
treated rats. The mitochondrial ATP/ADP
ratio decreased after tolcapone and DNP
treatments. Hepatotoxicity was expressed as
an increase in liver enzymes as well as
histopathological changes in tolcapone-
treated and to a lesser degree in DNP-treated
animals. No pathological findings in tissues
were observed in mice lacking COMT
activity.
The study showed that tolcapone has
potential hepatotoxic properties at high
doses in animals. The findings in vivo, at
the cellular level and in vitro are consistent
with those observed after treatment with
DNP, suggesting that hepatotoxic properties
of tolcapone may be due to uncoupling of
oxidative phosphorylation. Entacapone was
well tolerated and did not express any signs
related to uncoupling. Total depletion of
COMT activity did not induce any liver
problems in the knock-out mice, indicating
that hepatotoxicity is not a class effect of
these COMT inhibitors.
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ALAT alanine aminotransferase
AMP adenosine monophosphate
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max
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CNS central nervous system
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DA dopamine
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94. Introduction
The catechol-O-methyltransferase (COMT;
EC 2.1.1.6) enzyme was characterized by
Axelrod and Tomchick in 1958 (Axelrod
and Tomchick 1958; Axelrod and LaRoche
1959; Guldberg and Marsden 1975;
Männistö and Kaakkola 1999). COMT is
present in most mammalian tissues, with
the highest activities occurring in the liver
and kidneys (Guldberg and Marsden 1975;
Nissinen et al. 1988; Karhunen et al. 1994).
COMT catalyses the inactivation of
catecholamines by methylation of the 3-
hydroxyl group of the catechol ring both in
the periphery and the central nervous system
(CNS) (Figure 1, page 14). Besides
catecholamines, levodopa, the cornerstone
in treatment of Parkinson’s disease (PD), is
one of the substrates of COMT. The gradual
destruction of dopaminergic neurons in the
brain leads to a dopamine (DA) deficiency
and the onset of symptoms of PD (Schapira
2001; Orth and Schapira 2002). Levodopa
is administered together with dopa
decarboxylase (DDC) inhibitors, which
diminish the peripheral metabolism of
levodopa and increase its bioavailability
(Teräväinen et al. 2001). To induce further
increases of DA in the brain, COMT
inhibitors were designed to be used in the
treatment of PD as adjuncts to levodopa
and DDC inhibitors.
The first generation of COMT inhibitors
was developed during the 1960s. Pyrogallol
was reported to be a potent COMT
inhibitor already in 1959 by Axelrod and
LaRoche, and it was later used as a standard
inhibitor in the development of new agents
(Ross and Haljasmaa 1964a). Several of the
first-generation inhibitors were based on
catechol structure (Ross and Haljasmaa
1964a; 1964b; Baldessarini and Greiner
1973; Gugler and Dengler 1973). Gallates,
catechols, tropolone and its derivatives and
pyrogallol were all tested in vitro and in vivo
and appeared to be effective but were usually
extremely short-acting (Belleau and Burba
1961; Ross and Haljasmaa 1964a; Dorris
and Dill 1977). They were also toxic,
inducing convulsions in experimental
animals. In clinical trials with e.g. N-
butylgallate and U-0521, they were
established to be non-effective in the
treatment of PD, offering no advantage
when compared with dopa decarboxylase
(DDC) inhibitors administered together
with levodopa (Ericsson 1971). None of
the first-generation COMT inhibitors was
taken into routine clinical use.
Second-generation COMT inhibitors
were developed simultaneously by three
laboratories during the late 1980s
(Bäckström et al. 1989; Borgylua et al.
1989; Waldmeier et al. 1990). Approxi-
mately ten years later, a long-acting inhibitor,
BIA 3-202, with limited access to the brain,
was reported to have beneficial effects on
brain DA metabolism in the rat (Parada et
al. 2001). All of the second-generation
COMT inhibitors are selective and orally
active, and all except one are structurally
nitrocatechols.  Two of them were taken
into clinical use in the late 1990s.
Entacapone mainly acts peripherally, while
tolcapone crosses the blood-brain barrier
(BBB) and acts in both the periphery and
CNS (Männistö and Kaakkola 1999). Both
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are designed to be administered
concomitantly with levodopa, tolcapone
three times a day, and entacapone up to ten
times a day with each levodopa dose
(Dingemanse 1997; Männistö and
Kaakkola 1999). Although they are relatively
similar structurally, their kinetics and
metabolic pathways differ. In non-clinical
studies, both inhibitors proved to be safe
after undergoing extensive toxicity testing
in several animal species (Schläppi et al.
1996a; 1996b; 1996c; Tasmar Product
Monograph 1997; Entacapone Product
Monograph 1999). In clinical studies, they
were well tolerated, with the main side
effects being gastro-intestinal and
dopaminergic (Männistö and Kaakkola
1999).
After being on the market for about one
year and when 60 000 patients had been
exposed to tolcapone, the compound was
found to induce liver toxicity and three fatal
cases were reported within a short time span
(Assal et al. 1998; Mayoral et al. 1999;
Olanow 2000; Spahr et al. 2000; Watkins
2000). In 1998, the European Medicines
Evaluation Agency recommended
suspension of the marketing authorization
for tolcapone in the European Union
(European Medicine Evaluation Agency
1998). At the same time, the European
Medicines Evaluation Agency evaluated the
clinical data for entacapone and found no
reason to restrict its use.
Since entacapone and tolcapone are
structurally related nitrocatechols, concern
has arisen regarding hepatotoxicity of this
class of COMT inhibitors. As no signs of
liver toxicity in non-clinical studies or in
clinical trials of these inhibitors have been
observed, comparison of these agents at high
doses is the next logical step in evaluating
possible hepatotoxic properties and
mechanisms.
Introduction
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5. Review of the literature
5.1. COMT and catecholamine
metabolism
Catechol-O-methyltransferase (COMT) is
an intracellular enzyme that catalyses the O-
methylation of catechol-structured
compounds, such as catecholamine neuro-
transmitters, catechol hormones and
xenobiotic catechols, in a variety of tissues
in mammals (Figure 1, page 14) (Axelrod
and Tomchick 1958; Guldberg and
Marsden 1975; Bonifati and Meco 1999).
The COMT enzyme was initially
characterized in the 1950s, when both
adrenaline (A) and noradrenaline (NA) were
found to undergo an O-methylation
reaction (Axelrod 1957). Adrenaline was
metabolized in the rat liver fraction in the
presence of S-adenosylmethionine and
magnesium ions to metanephrine. This led
to the finding that endogenous amines,
including NA, A and dopamine (DA), are
O-methylated to normetanephrine,
metanephrine and 3-methoxytyramine,
respectively, when S-adenosylmethionine
donates its methyl group to one of the
hydroxy groups of catecholamines (Axelrod
and Tomchick 1958). Later it has been
found that besides A, NA and DA, the
physiological substrates of COMT also
include 3,4-dihydroxyphenylalanine
(DOPA) and catecholestrogens (Guldberg
and Marsden 1975; Männistö and Kaakkola
1999). These amines are inactivated by
methylation of the 3-hydroxyl group of the
catechol ring, and COMT catalyses this
reaction using S-adenosyl-L-methionine as
the methyl donor. In the 1970s, the presence
of two distinct forms of COMT in rat
erythrocytes was demonstrated (Assicot and
Bohuon 1971): one fraction was in soluble
form (S-COMT), and the other was bound
to membranes (MB-COMT) (Assicot and
Bohuon 1971; Borchardt et al. 1974).
Cellular and tissue distribution of COMT
The distribution and cellular localization of
COMT have been evaluated in man and in
several animal species (Guldberg and
Marsden 1975; Nissinen et al. 1992;
Karhunen et al. 1994). The highest activity
of COMT is found in the liver and kidney,
but activity has also been detected in several
other organs, including the brain, lung,
spleen, mammary gland, uterus, stomach,
intestines and adrenals (Guldberg and
Marsden 1975; Nissinen et al. 1988;
Karhunen et al. 1994; De Santi et al. 1998).
Axelrod and Tomchick compared liver
COMT activities in several mammalian
species and found the highest activity in the
rat, followed by the mouse and guinea pig,
while the activity of COMT in human liver
was about one-tenth of that in the rat liver
(Axelrod and Tomchick 1958; Guldberg
and Marsden 1975). Although MB-
COMT represents only 2-10% of total
COMT activity in the rat liver and brain, it
has a 3- to 100-fold higher affinity for
catechol substrates than S-COMT, thus
being responsible for O-methylation at
physiologically relevant concentrations of
neurotransmitters (Assicot and Bohuon
1971; Aprille and Malamud 1975; Rivett
et al. 1983; Jeffery and Roth 1984; Roth
1992). The activity of S-COMT pre-
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dominates when MB-COMT is saturated
(Roth 1992; Vieira-Coelho and Soares-da-
Silva 1999). The subcellular localization of
MB-COMT using rat liver preparations has
been postulated to be on mitochondrial or
plasma membranes (Grossman et al. 1985;
Tilgmann et al. 1992). Ulmanen et al.
(1997) have shown by immuno-
cytochemistry in cell culture studies using
both mammalian cell lines and rat primary
neurons that MB-COMT is located on
intracellular membranes like the rough
endoplasmic reticulum rather than on
plasma membranes, while S-COMT is
expressed both in the nuclei and cytoplasm.
In the mouse liver, most of the COMT
activity is associated with membranes
(Aprille and Malamud 1975). The liver
membranes contain 70-90% of the total
COMT activity in homogenate. The
specific activity in mouse membranes is 8
to 9-fold higher than that in rat membranes,
whereas the activity of S-COMT is
comparable in the mouse and rat (Aprille
and Malamud 1975).
S-COMT is the predominant form of
the enzyme expressed in the periphery of
most rat tissues (Karhunen et al. 1994; Lotta
et al. 1995). Rat liver shows highest activity
for S-COMT, while the lowest activity of
both S-COMT and MB-COMT is found
in the heart (Ellingson et al. 1999). MB-
COMT is detected mainly in the liver and
kidneys and in smaller amounts in the brain
and intestines (Karhunen et al. 1994). The
cellular localization of S-COMT in rat liver
is limited to hepatocytes, and Kuppfer cells
show no activity (Karhunen et al. 1994).
Using immunohistochemical staining
methods, S-COMT has been found to be
the major form in the rat brain with non-
neuronal localization (Karhunen et al. 1994).
The most intensely stained areas were lateral,
third and fourth ventricles, followed by cells
of the choroid plexus (Karhunen et al.
1994).
In the human liver, the activity is
significantly higher in men than in women,
and it increases with age (Agathopoulos et
al. 1971; De Santi et al. 1998). MB-
COMT is distributed among all tissues,
with the highest levels being found in the
liver (Roth 1992). In the human brain, both
isoforms of COMT are present, but MB-
COMT is the functionally significant form
(Roth 1992; Karhunen et al. 1994; Hong
et al. 1998). Since the highest ratio of MB-
COMT to S-COMT is found in brain
tissue, this suggests that MB-COMT may
be localized in neuronal cells of the CNS in
man (Roth 1992; Tenhunen et al. 1994).
In human breast tissue, COMT, but no
other methyltransferase enzyme, has been
reported to be present (Assicot et al. 1977).
An increase in COMT activity has been
observed in the majority of primary
mammary carcinoma samples of high
malignancy (Assicot et al. 1977; Hoffman
et al. 1979). Using immunocytochemical
staining methods, S-COMT has been
localized in the cytoplasm of epithelial cells
of secretory tubules in both human and
rodent mammary glands; there is a strong
reaction in malignant cells, particularly in
tumours (Amin et al. 1983; Tenhunen et
al. 1999). In human mammary epithelial
cells, nuclear COMT has been observed in
normal cells as well as cancer cells (Weisz et
al. 2000).
Review of the literature
13
5.2. Other catecholamine-
metabolizing enzymes
Other metabolic pathways in inactivating
catecholamines include oxidative removal
of their amino group by monoamine oxidase
(MAO) and sulphoconjugation by
phenolsulphotransferase (PST) (Kopin
1994) (Figure 1). MAO metabolizes
catecholamines to 3-methoxy-4-
hydroxyphenylglycol. There are two
isozymes of MAO, A and B, which have
slightly different substrates; e.g. NA is
preferentially metabolized by MAO-A,
whereas DA is a substrate of both types in
most species (O’Carroll et al. 1983; Kopin
1994). In the human brain, approximately
70% of total MAO activity is of type B,
which oxidizes most of the DA in man
(Riederer et al. 1986). However, in rodents,
DA is oxidized mainly by MAO-A
(Johnston 1968).
Cellular and tissue localization of MAO
In the periphery, MAO is expressed in
several mammalian tissues, the highest
concentrations being in the liver and kidney
(Kalaria and Harik 1987; Kopin 1994).
Some tissues, e.g. bovine liver and kidney,
contain mainly MAO-B, whereas rat
skeletal muscle contains only minor
amounts of both forms (Shih et al. 1999b).
In the brain, the distribution of MAO-
A and -B shows little species variation.
MAO-A is predominantly found in
catecholaminergic neurons, MAO-B is
most abundant in serotonergic and
histaminergic neurons and glial cells, being
the dominant isozyme in the human brain
(Kopin 1985; Riederer et al. 1986; Kalaria
and Harik 1987; Shih et al. 1999b). Both
MAO isozymes are located on the outer
mitochodrial membrane.
Role of PST
Sulphation of catecholamines is performed
by several types of PST (Kopin 1985). The
highest PST concentrations are observed in
the rat brain and liver, but enzyme activity
is also found in the adrenals, lung, kidneys
and testes (Foldes and Meek 1974). In the
rat, sulphoconjugation of 3,4-
dihydroxyphenylacetic acid (DOPAC) and
homovanillic acid (HVA) plays a more
important role than in e.g. dogs and
primates (Kopin 1985).
Gene-manipulated mice deficient in
catecholamine-metabolizing enzymes
The effects of total COMT or MAO
inhibition in the brain has been evaluated
in COMT- or MAO-deficient mice (Gogos
et al. 1998; Shih et al. 1999a; Huotari et al.
2002). In COMT knock-out mice, striatal,
hypothalamic and cortical MAO-dependent
metabolite DOPAC and 3,4-dihydroxy-
phenylglycol (DHPG) levels were increased,
and COMT-dependent metabolites HVA
and 3-methoxy-4-hydroxyphenylglycol
were absent in mice lacking the Comt -gene.
A trend for DA and NA to increase in striatal
and hypothalamic brain homogenates of
COMT knock-out mice has also been found
(Huotari et al. 2002). Gogos et al. (1998)
reported slightly aggressive behaviour of
male heterozygous mice. Mice lacking
MAO-A or MAO-B have been observed
express different changes in behaviour (Shih
et al. 1999b). Since MAO-A is reported to
be responsible for 5-hydroxytryptamine,
NA and DA metabolism, mice deficient in
MAO-A have elevated brain levels of 5-
hydroxytryptamine and thus show more
aggressive behaviour. MAO-B is responsible
Review of the literature
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for phenylethylamine metabolism and
knock-out animals do not exhibit aggres-
sion (Shih et al. 1999b).
In humans, due to the role of MAO in the
metabolism of catecholamines in the brain,
both MAO-A and MAO-B inhibitors have
been taken into clinical use.  Selective
inhibition of MAO-B by e.g. selegiline is
used in the treatment of PD to increase the
concentration of DA in the human brain
independently of levodopa (Deleu et al.
2002).
Figure 1. Biosynthesis and catabolism of catecholamines. DOPA, 3,4-dihydroxyphenylalanine;
DA, dopamine; NA, noradrenaline; A, adrenaline; NM, normetanephrine; DOMA, 3,4-
dihydroxymandelic acid; MN, metanephrine; VMA, vanillylmandelic acid; 3-MT, 3-
methoxytyramine; DOPAC, 3,4-dihydroxyphenylacetic acid; DHPG, 3,4-dihydroxyphenylglycol;
HVA, homovanillic acid; MHPG, 3-methoxy-4-hydroxyphenylglycol; 3-OMD, 3-O-
methyldopa.
5.3. COMT inhibitors in the
treatment of Parkinson’s disease
5.3.1. Rationale for the use of COMT
inhibitors
In Parkinson’s disease, dopaminergic
neurons in the brain are gradually destroyed,
leading to a DA deficiency. When clinical
symptoms appear, ca. 70-80 % of the
dopaminergic neurons have already been lost
(Schapira 2001; Teräväinen et al. 2001; Orth
and Schapira 2002). The decrease in DA
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levels in the striatum provokes the typical
symptoms of PD (Schapira 2001). The
aetiology of neuronal destruction is
unknown. More than one aetiological factor
has been postulated to cause PD, including
genetic and environmental factors (Orth and
Schapira 2002). Levodopa, the most
effective symptomatic treatment available
for PD, has been in clinical use since the
1960s (Birkmayer and Hornykiewicz
1961). Levodopa is a DA precursor, that
can cross the BBB and is further
decarboxylated to form DA. In the
periphery, after oral administration,
approximately 70% of levodopa is
metabolized to DA by dopa decarboxylase
(DDC). As a COMT substrate, a smaller
amount of levodopa is metabolized by
COMT through O-methylation to form
3-O-methyldopa (3-OMD) (Figure 2).
Peripherally acting selective DDC inhibitors,
such as carbidopa and benserazide, have been
used as adjuncts to levodopa treatment in
PD patients (Bartholini and Pletscher 1975;
Rivest et al. 1999). DDC inhibitors increase
the bioavailability of levodopa in the brain,
but due to the increased metabolism by the
COMT pathway, less than 10% of the
levodopa dose reaches the brain (Nutt and
Fellman 1984; Männistö and Kaakkola
1990). The plasma concentration of 3-
OMD increases due to the long half-life of
levodopa
DA DA
COMT
inhibitor
DDC inhibitor
3-OMD
levodopa
3-OMD
COMT
inhibitorBBB
Figure 2. Effect of COMT inhibitors on levodopa metabolism. DA, dopamine; 3-OMD, 3-O-
methyldopa; DDC, dopa decarboxylase; BBB, blood-brain barrier.
Periphery Brain
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this metabolite and remains high during
chronic therapy (Kuruma et al. 1971). The
methylated product may further reduce the
utilization of levodopa by competing with
it on the BBB level (Nutt and Fellman
1984; Reches and Fahn 1984; Männistö
and Kaakkola 1990). By blocking the O-
methylation pathway of levodopa, COMT
inhibitors increase its bioavailability and
reduce the formation of 3-OMD in PD
patients (Männistö 1994). With
concomitant use of COMT inhibitors and
levodopa, daily doses of levodopa can be
reduced while retaining the clinical benefit
(Nutt et al. 1994; Kurth et al. 1997). The
administration of COMT inhibitors to PD
patients slows the elimination of levodopa
from the plasma, which increases the ON
time in these patients (ON time, sudden
return of effectiveness that may be
accompanied by hyperkinesia) (Fahn 1974;
Nutt et al. 1994; Dingemanse 1997).
In the brain, reuptake of catecholamines
into presynaptic neurons and metabolism
by MAO are the most important routes in
eliminating released catecholamines;
COMT plays only a minor role. COMT
inhibition is reported not to alter
catecholamine levels in plasma noticeably
(Illi et al. 1994; Li et al. 1998; Männistö
and Kaakkola 1999; Rojo et al. 2001).
5.3.2. First-generation COMT
inhibitors
Following description and partial
characterization of the COMT enzyme in
the late 1950s and the reported occurrence
of 3-O-methylated metabolites of
catecholamines in mammals, the develop-
ment of first-generation COMT inhibitors
began (Axelrod and Tomchick 1958). These
inhibitors include e.g. pyrogallol and its
derivatives, tropolones, 3,4-dihydroxy-2-
methylpropiophenone (U-0521) and
catechol. The COMT inhibition activity of
all of these compounds was weak or non-
selective, they had poor bioavailability and
they tended to be short-acting. None of the
first-generation COMT inhibitors was
therefore taken into routine clinical use
(Ericsson 1971; Reches and Fahn 1984).
Pyrogallol (1,2,3-trihydroxybenzene)
(Figure 3) was shown to be a potent COMT
inhibitor in vitro and in vivo by Axelrod and
LaRoche in 1959. It was a good substrate
of COMT, acting as a competitive inhibitor,
and had a short duration in vivo (Belleau
and Burba 1961), but it induced toxic effects
due to properties other than COMT
inhibition (Wylie et al. 1960; Angel and
Rodgers 1968). Pyrogallol acts both in the
CNS and periphery (Angel and Rodgers
1968), but with regular use for two weeks,
COMT activity in the rat heart and brain
showed no major changes after a sub-
cutaneous daily dose of 50 mg/kg (Maitre
1966). While pyrogallol is not suitable for
clinical use because of these properties, it
has been used as a tool in studies on COMT
inhibition.
Gallates are effective COMT inhibitors
in vitro and in vivo but have an extremely
short duration of action in the rat, only 15-
30 minutes after an intraperitoneal injection
(Dorris and Dill 1977). A few clinical trials
performed with N-butyl gallate (Figure 3)
failed to reveal any advantage over DDC
inhibitors administered together with
levodopa (Ericsson 1971). When ten
parkinsonian patients in whom the
maximum dosage of levodopa had been
reached were treated with an initial dose of
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N-butyl gallate 250 mg, followed by
increasing doses of up to 750 mg daily, the
symptoms were alleviated. However, the
clinical improvement was not as effective
as that obtained with DDC inhibitors
(Ericsson 1971).
Catechol (1,2-dihydroxybenzene) and
several of its derivatives are COMT
inhibitors in vitro and in vivo (Ross and
Haljasmaa 1964a; Baldessarini and Greiner
1973), but they are toxic in vivo because of
properties unrelated to COMT inhibition
(Angel and Rodgers 1968; Bakke 1970).
Some of them, e.g. catechol-configurated
flavonoids, are more potent inhibitors of
COMT in vitro than pyrogallol (Gugler and
Dengler 1973). Catechol itself is highly
toxic, inducing convulsions in the rat after
an oral dose of 100 mg/kg (Angel and
Rodgers 1968; Bakke 1970). U-0521 (3,
4-dihydroxy-2-methylpropriophenone)
(Figure 3) was reported to effectively
diminish plasma and brain 3-O-methyldopa
(3-OMD), enhancing the accumulation of
both DOPA and DA in rat striatum after
an intraperitoneal injection of 100 mg/kg
or more (Fahn et al. 1979; Reches and Fahn
1984). However, it was not effective when
administered orally to rats or in clinical use
with parkinsonian patients (Fahn et al.
1979; Reches and Fahn 1984).
Tropolone (2-hydroxycyclohepta-
trienone) (Figure 3) and its derivatives
inhibit both peripheral and central COMT
in vitro and in vivo but are short-acting
(Belleau and Burba 1961; 1963; Ross and
Haljasmaa 1964a). The inhibitory effects
are comparable with those of pyrogallol in
the periphery; however, in the brain,
tropolone shows much less activity than
pyrogallol (Ross and Haljasmaa 1964a;
1964b). Tropolone 100 mg/kg
administered intraperitoneally caused an
increase in DA and DOPAC concentrations
in rat striatum, while simultaneously
reducing the concentration of HVA (Broch
1972). However, the central COMT
inhibition was quite modest and was not
correlated with the concentration of
tropolone. Moreover, tropolones have been
reported to be toxic in mice, rats and rabbits
at doses inducing convulsions (Ri 1951).
Since the majority of first-generation
COMT inhibitors had metal-chelating
properties, a chelation mechanism was
proposed for complex formation between
catecholamines and the COMT enzyme
(Senoh et al. 1959). Metal chelators of
various structures were tested in vitro in
mouse brain homogenates for their capacity
to inhibit the COMT enzyme. Some of
these compounds, e.g. 8-hydroxyquinoline,
were more potent COMT inhibitors than
pyrogallol in vitro, but the majority failed
to express any COMT inhibitory effects in
mouse brain extract in vitro, indicating that
the metal-chelating effect alone was
insufficient to produce COMT inhibition
(Ross and Haljasmaa 1964a).
5.3.3. Second-generation COMT
inhibitors entacapone and tolcapone
A new generation of COMT inhibitors was
discovered in the 1980s,and these
compounds were shown to inhibit COMT
and to alter levodopa metabolism in vivo.
Entacapone, tolcapone, nitecapone and the
recently described BIA 3-202 and 3-335 are
all structurally nitrocatechols, while CGP
28014 is a pyridine derivative (Figure 3)
(Nissinen et al. 1988; Borgylua et al. 1989;
Waldmeier et al. 1990; Parada et al. 2001;
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Figure 3. Structure of first-generation COMT inhibitors (pyrogallol, tropolone, n-Butyl gallate,
U-0521), second-generation inhibitors (entacapone, tolcapone, nitecapone, BIA 3-202, CGP
28014) and the uncoupling agent 2,4-dinitrophenol.
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Bonifacio et al. 2002). The nitrocatechol-
structured COMT inhibitors entacapone
and tolcapone are known as tight-binding
inhibitors, but the binding to COMT is
reversible (Nissinen et al. 1992; Lotta et al.
1995). They are highly selective inhibitors
with virtually no action on tyrosine
hydroxylase, dopamine ß-hydroxylase,
DDC or MAO-A and MAO-B (Bäckström
et al. 1989; Zürcher et al. 1990b).
Entacapone acts mainly peripherally,
whereas tolcapone crosses the BBB (Zürcher
et al. 1990a; Nissinen et al. 1992;
Dingemanse 1997).
Pharmacology in vitro and in vivo
Entacapone selectively inhibits rat S-
COMT from the duodenum, liver, brain
and erythrocytes at low nanomolar
concentrations in vitro (Nissinen et al.
1992). After an oral dose of 10 mg/kg
entacapone S-COMT acitivity is greatly
reduced in rat duodenum, liver and
erythrocytes. The longest duration of
inhibition is in the duodenum, but striatal
COMT activity is suppressed only
transiently (Nissinen et al. 1992).
Tolcapone, by contrast, markedly inhibits
both peripheral and central COMT
(Zürcher et al. 1990b). In several human
peripheral organs (liver, kidneys,
duodenum, lungs), both entacapone and
tolcapone have been shown to be potent
COMT inhibitors ex vivo (De Santi et al.
1998). Hepatic COMT activity of human
liver ex vivo was inhibited by entacapone at
an IC
50
 151 nmol/l, while that for
tolcapone was 773 nmol/l; the results for
other organs were similar (De Santi et al.
1998).
Oral entacapone administered together
with levodopa and carbidopa to rats or
cynomolgus monkeys reduced the
formation of 3-OMD and elevated serum
levodopa levels (Cederbaum et al. 1991;
Nissinen et al. 1992). The increases in
levodopa, DA and DOPAC concentrations
were dose-dependent, and the lowest
effective dose in the rat was 3 mg/kg, which
also reduced 3-OMD concentrations
(Nissinen et al. 1992). However, even at a
dose of 30 mg/kg, the HVA concentration
in the rat was not decreased, indicating that
central COMT activity is not inhibited by
entacapone (Nissinen et al. 1992).
Tolcapone, in contrast, induced about 90%
decrease in the levels of HVA and 3-MT in
the rat brain at the dose of 30 mg/kg p.o.
(Zürcher et al. 1990b). After oral
administration to rats, tolcapone 0.2 mmol
(54.6 mg/kg) markedly reduced the
peripheral metabolism of exogenous DOPA
(100 mg/kg p.o.) to 3-OMD when given
together with benserazide (50 mg/kg p.o.),
thus increasing the bioavailability of DOPA
in the brain (Zürcher et al. 1990b).
Tolcapone inhibits brain COMT activity
in the rat at single doses of 3-10 mg/kg,
while 30 mg/kg or more of entacapone is
needed for temporary suppression of
COMT activity (Zürcher et al. 1990a;
Männistö et al. 1992a; 1992b). Extracellular
DOPAC tends to increase and HVA to
decrease in the rat striatum after a dose of
10 mg/kg tolcapone intraperitoneally,
whereas the respective dose of entacapone
has no effect (Kaakkola and Wurtman
1993). At an intraperitoneal dose of 30 mg/
kg, neither entacapone nor tolcapone has
any effect on extracellular levels of free
catecholamines in the brain of anaesthetized
rats, although tolcapone does reduce
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COMT-dependent metabolites (Li et al.
1998). In rabbits, 30 mg/kg of tolcapone
intravenously increases catecholamine
baseline levels in plasma ca. 300% (Garrido
et al. 1994).
In vivo Parkinson animal models
Proof of principle has been shown in animal
models of PD for both entacapone and
tolcapone. When neurological deficits
resembling those seen in PD were induced
in monkeys by administration of neurotoxin
1-methyl-4-phenyl-1,2,3,6-tetrahydro-
pyridine, co-administration of entacapone
12.5 mg/kg p.o. or tolcapone 15 or 30 mg/
kg p.o. prolonged the antiparkinsonian
activity of levodopa/carbidopa (Smith et al.
1997; Tasmar Product Monograph 1997).
Unilateral destruction of dopaminergic
neurons in the substantia nigra of rats by
neurotoxin 6-hydroxydopamine led to
contralateral circling behaviour when rats
were treated with levodopa/carbidopa.
Entacapone 3 or 10 mg/kg and tolcapone
30 mg/kg prolonged the circling response
to levodopa/carbidopa in these rats (Da
Prada et al. 1993; Törnwall and Männistö
1993).
Entacapone and tolcapone inhibit both
S- and MB-COMT, but tolcapone inhibits
MB-COMT 10 times more effectively than
entacapone (Lotta et al. 1995). Tolcapone
is very potent in inhibiting MB-COMT in
rat liver and brain tissue in vivo after oral
administration (Vieira-Coelho and Soares-
da-Silva 1999). However, the expression of
MB-COMT in tissues is far less than that
of S-COMT, although the former possesses
higher affinity for catecholamines than the
S-COMT (Guldberg and Marsden 1975;
Lotta et al. 1995).
Acute toxicity of both entacapone and
tolcapone is low; oral LD
50
 values in the rat
are higher than 2 g/kg, and toxicity is not
modified by the combined administration
of levodopa and carbidopa (Borgulya et al.
1991; Törnwall and Männistö 1991;
Kaakkola et al. 1994). The metabolic routes
of tolcapone are more complicated than
those of entacapone. The main metabolic
pathway for entacapone and tolcapone is
glucuronidation, but tolcapone is also
metabolized through methylation,
reduction and hydroxylation (Wikberg et
al. 1993; Dingemanse et al. 1995).
Clinical use
The symptoms of PD are alleviated by
administration of levodopa. It improves the
disability of patents with PD more than any
other drug. Since levodopa is actively
metabolized, it is given concomitantly with
DDC inhibitors, which inhibit the
conversion of levodopa to DA, thus
increasing its bioavailability. However, most
of the exogenous levodopa is methylated
to 3-OMD by COMT. The administration
of entacapone or tolcapone together with
levodopa and a DDC inhibitor increases
plasma concentrations of levodopa dose-
dependently without significantly affecting
the peak plasma concentration of levodopa
(Nutt et al. 1994; Fahn 1998; Teräväinen
et al. 2001). The concentrations of DOPAC
and HVA, the main metabolites of DA, are
increased after treatment with entacapone,
while after tolcapone DOPAC is increased
and HVA decreased. Although the central
actions of entacapone and tolcapone differ,
systemic administration leads to an increased
level of DA in the brain. Both inhibitors
are eliminated rapidly after an oral dose. The
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plasma elimination half-life after entacapone
is about 1-2 hours, whereas the half-life of
tolcapone is approximately 2-3 hours. The
bioavailability of entacapone (35%) is less
than that of tolcapone (65%). Entacapone
is 98% and tolcapone 99.9% bound to
plasma proteins. Since entacapone is
metabolized more rapidly than tolcapone,
it is administered in clinical use up to 10
times a day with each dose of levodopa,
while tolcapone is administered three times
a day. Both inhibitors provide benefits to
parkinsonian patients in concomitant
dosing with levodopa (Keränen et al. 1994;
Dingemanse 1997; Männistö and Kaakkola
1999). One to two months’ treatment with
entacapone or tolcapone at a clinical dose
of 200 mg (entacapone with each levodopa
dose, tolcapone three times daily) inhibits
the formation of 3-OMD by 50% and
80%, respectively (Kaakkola 2000). Both
entacapone and tolcapone significantly
increase the ON time and decrease the OFF
time in patients with advanced PD
(Kaakkola 2000). The increase in daily ON
time varies from 1 to 2 hours with
entacapone and from 0 to 2.5 hours with
tolcapone (Kaakkola 2000).
The plasma levels of DA, NA, A and total
catecholamines were reported to increase in
seven out of eight PD patients at a mean
tolcapone dose of ca. 270 mg/day (Rojo et
al. 2001). One patient simultaneously had
elevated liver enzymes and a 513% increase
in catecholamine levels. Entacapone has not
been reported to change plasma cate-
cholamine levels in healthy volunteers (Illi
et al. 1994; Scheinin et al. 1998).
5.4. Drug induced hepatotoxicity
Although most hepatotoxic compounds are
detected during non-clinical testing and are
not developed further, hepatotoxicity
remains the leading cause of withdrawal of
drugs from the market (Lasser et al. 2002;
Thomas 2002). This is because drug-
induced hepatotoxicity is generally only seen
after a drug has been marketed and used by
tens of thousands of patients, as opposed
phase II clinical trials with limited numbers
of participants (Batt and Ferari 1995; Lasser
et al. 2002).
5.4.1. Mechanisms, clinical symptoms
and signs of hepatotoxicity
Drug-induced hepatotoxicity is typically
observed as a hepatocellular or cholestatic
injury (Watkins 2000). Cholestatic injury
is reflected as a selective interference of the
drug with the liver’s ability to make and
secrete bile (Watkins 2000). In humans, it
is characterized by an elevation in serum
alkaline phosphatase (APHOS) and
bilirubin. In liver tests, cholestatic injury is
suspected when the value of APHOS is two
times the upper limit of normal (ULN) or
the ratio of alanine transaminase (ALAT)
to APHOS is less than two (Benichou
1990; Kaplowitz 2001). However, in the
rat, APHOS is predominantly of intestinal
origin, and thus, it cannot be used as a
biomarker of cholestatic injury as such but
should be used together with γ-glutamyl
transferase and bilirubin (Loeb and Quimby
1999). In hepatocellular injury, liver cells
are damaged, and the toxic signs manifest
as a rise in clinical serum chemistry para-
meters (Benichou 1990; Kaplowitz 2001).
In man, alanine aminotransferase (ALAT),
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as a relatively liver-specific enzyme, is the
most useful marker of hepatocellular injury
in patients. In animals, especially in mice,
rats and dogs, hepatic ALAT activity is 3-
10 times higher than in any other tissue
(Loeb and Quimby 1999). ALAT is
localized both the cytoplasma and
mitochondria of cells, but the activity is
several times higher in the former. It is
released to serum when liver cells are dying,
thus elevating the normal levels of serum
ALAT. In patients, a serum ALAT level two-
or threefold the ULN or an ALAT/APHOS
ratio of five or more is considered clinically
significant and a sign of hepatocellular liver
injury (Benichou 1990; Dossing and Sonne
1993; Watkins 2000; Kaplowitz 2001). In
non-clinical toxicity studies, ALAT is used
as a marker of hepatocellular injury, with
activity values of treated and untreated
control animals being compared. In
addition to ALAT activity, increased sorbitol
dehydrogenase (SDH) activity appears early
in the course of liver injury in animals. SDH
is a cytosolic enzyme with the highest
activity in the liver and kidneys. A positive
correlation between increased ALAT and
SDH activities and hepatocellular changes
in the rat has been reported (Travlos et al.
1996). ALAT activity is cleared in about
four days, and SDH activity returns to
normal even faster (Mizrahi et al. 1987;
Loeb and Quimby 1999). Although both
these enzymes are located periportally in the
liver, the main target for the injury is the
centrilobular area due to diminished oxygen
during the passage through periportal areas
to the centrilobular area (Haschek et al.
2002). A few reports are available on
histological hepatic necrosis in connection
with the elevation of serum ALAT in rats
and dogs (Balazs et al. 1961; Loeb and
Quimby 1999). Balazs et al. (1961) have
reported a distinct correlation between
ALAT activity and the degree of necrosis,
although in other studies the correlation is
less clear (VanVleet and Alberts 1968). It
has been postulated that due to changed
permeability of the cell membranes ALAT
and SDH can leak into serum before cell
death and that histological necrosis is seen
variably (Loeb and Quimby 1999).
The lack of specific clinical or histological
features of drug-induced liver lesions is one
of the reasons behind the sporadic incidence
of liver injury since injuries produced by
drugs may be indistinguishable from those
due to other reasons (Dossing and Sonne
1993; Watkins 2000). Some drugs cause
liver toxicity in a dose-related manner with
a reaction arising only after a sufficient
amount of the drug is taken. Dose-
independent reactions occur as a rare
complication of therapeutic doses of the
drug (Dossing and Sonne 1993).
Hepatocellular necrosis can occur within
minutes after a toxic insult and is usually
associated with severe metabolic
disturbances. Cell necrosis is a typical
consequence of acute hepatic injury. The
onset of cell death is characterized by
breakdown of the plasma membrane
permeability barrier, which leads to loss of
metabolic intermediates, leakage of enzymes
and collapse of all electrical and ionic
gradients across the plasma membrane
(Mehendale et al. 1994). Fountoulakis et
al. (2002) reported a threefold elevation of
ALAT six hours after carbon tetrachloride
dosing of rats, and at 24 hours, the increase
in ALAT values was extremely pronounced.
Typical centrilobular hepatocellular
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necrosis induced by carbon tetrachloride is
reported to be associated with catecholamine
release (Schwetz and Plaa 1969; Roberts et
al. 1997). A and NA can potentiate the
sensitivity of the liver to carbon
tetrachloride, but administered alone they
fail to induce any toxicity. The toxicity is
characterized by increased serum
aminotransferase activities and hepato-
cellular necrosis (Schwetz and Plaa 1969).
Endogenous A and NA are also capable of
potentiating the toxicity induced by carbon
tetrachloride, as well as several other
adrenergic drugs, in the rat (Roberts et al.
1997). The mechanism behind the
adrenergic agents’ increased toxicity is
suggested to be related to induced hypoxia
within the liver cells (Zempel et al. 1983).
5.4.2. Hepatotoxicity induced by
COMT inhibitors
The first-generation COMT inhibitors have
been studied in relation to hepatotoxic
properties.  Tropolone has been reported to
induce non-specific hepatitis in mice in vivo
after a single dose of 400 mg/kg; this is also
the oral LD
50
 for mice (Table 1) (Ri 1951;
Nakagawa and Tayama 1998). In isolated
rat hepatocytes, tropolones induced a dose-
and time-dependent loss of cell viability,
which is associated with a decrease of
intracellular adenosine triphosphate (ATP)
(Ri 1951; Nakagawa and Tayama 1998).
Tropolone is also reported to suppress the
growth of murine hepatocytes, with the IC
50
being ca. 1.23 µg/ml (Inamori et al. 1993).
Gallates induced a concentration-depen-
dent cell death in rat hepatocytes in vitro,
which was preceded by the depletion of ATP
(Table 1) (Nakagawa and Tayama 1995).
Since propyl gallate also induced an increase
in state 4 oxygen consumption in isolated
rat liver mitochondria, the cytotoxicity is
linked to uncoupling of oxidative
phosphorylation (Nakagawa and Tayama
1995).
The non-clinical toxicity studies
performed for the marketing applications
of second-generation COMT inhibitors
entacapone and tolcapone revealed no signs
of  hepatotoxicity (Eckhardt et al. 1996;
Schläppi et al. 1996a; 1996b; 1996c; Tasmar
Product Monograph 1997; Entacapone
Product Monograph 1999). In non-clinical
studies with tolcapone in mice, only slight
to moderate hepatocellular hypertrophy was
observed after 18 months’ treatment (dose
not given) (Olanow 2000).
In vivo, COMT inhibition alone has not
been reported to induce hepatotoxicity.
COMT knock-out mice, developed by
means of homologous recombination in
embryonic stem cells leading to a mouse
strain in which the gene encoding the
COMT enzyme is disrupted, have shown
no signs of liver injury (Gogos et al. 1998;
Huotari et al. 2002). The mice have been
viable and fertile, with only minor changes
in catecholamine metabolism (Huotari et
al. 2002).
The first-generation COMT inhibitors
were not taken into clinical use because of
properties connected to short duration of
action, toxicity or inefficiency in clinical
studies (Ericsson 1971; Reches and Fahn
1984). Hepatotoxic signs were observed in
clinical use up to 12 weeks with N-butyl
gallate, when markedly abnormal ALAT
activities (values not given) were reported
in four out of 11 patients receiving dosages
above 2250 mg daily (Simpson and Varga
1972).
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The use of entacapone has been reported
to be associated with hepatotoxicity in one
patient after three weeks’ treatment (Fisher
et al. 2002). Two other cases were earlier
reported to the Australian Adverse Drug
Reaction Advisory Committee (ADRAC).
However, in two of these three cases, the
patients had concomitant medications with
hepatotoxic potential, and the third case had
a history of long-standing alcohol abuse and
alcohol-induced liver cirrhosis (Beck et al.
2002). In none of these cases was
hepatotoxicity hepatocellular, instead being
cholestatic injury in terms of ALAT activity
or the ALAT/APHOS ratio (Watkins 2000;
Kaplowitz 2001).
In clinical use of tolcapone, severe
hepatotoxicity has been observed in several
PD patients (Table 1). A total of nine cases
of abnormal hepatic reactions have been
reported, three with a fatal outcome (Assal
et al. 1998; Bonifati and Meco 1999;
Colossimo 1999; Olanow 2000). In
November 1998, marketing authorization
for tolcapone was suspended in the
European Union because of increasing
concern about reports of severe
hepatotoxicity (European Medicines
Evaluation Agency 1998). Findings of severe
centrilobular hepatic necrosis with
inflammatory infiltrates (plasma cells,
eosinophils) due to tolcapone treatment
were reported in three parkinsonian patients
(Olanow 2000). In one patient who died
after tolcapone treatment, fulminant
hepatitis was verified histologically (McCaul
et al. 1986; Spahr et al. 2000). In all three
tolcapone-treated patients, ALAT was
increased to at least three times the ULN
(Olanow 2000). The incidence of hepatic
failure was 10-100 times higher than in the
general population (Mayoral et al. 1999).
In clinical trials, 3.5% of tolcapone-treated
patients had elevated liver enzymes three
times higher than the ULN compared with
only 1% of placebo-treated patients
Table 1. Hepatotoxic properties of COMT inhibitors.
COMT Toxicity to hepatocytes In clinical use Reference
inhibitor In vitro In vivo Serum Liver
aminases toxicity
Tropolone yes hepatitis not in not in Ri 1951; Inamori et al. 1993;
clinical use clinical use Nakagava and Tayama1998
Gallates yes no data ↑ NAD Simpson and Varga 1972;
Nakagava and Tayama
1995
U-0521 no data no data NAD NAD Reches and Fahn 1984
Entacapone no data NAD NAD NAD Keränen et al. 1994;
Vaalavirta et al. 1998
Tolcapone no data necrosis ↑ hepatitis Assal 1998; Vaalavirta et al.
1998; Olanow 2000
NAD = no abnormalities detected
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(Mayoral et al. 1999; Watkins 2000). In
addition, a clear dose-response effect was
evident.
5.5. Uncoupling as a
phenomenon
In healthy cells, ATP-driven Ca2+ pumps
maintain a Ca2+ gradient across the plasma
membrane. Since calcium precipitates are
prominent in necrotic tissue, an increase in
free Ca2+ may be one of the first responses
to cell injury. However, in at least some
models of drug-induced liver injury caused
by hypoxia, Ca2+ does not rise before the
toxic lesion (Harman et al. 1992;
Mehendale et al. 1994). Uncouplers of
oxidative phosphorylation, such as Br-
A23187, can cause bioenergetic cell death
rather than Ca2+-mediated cell killing
(Mehendale et al. 1994). Thus, cell killing
in models of hypoxic injury to hepatocytes
is not dependent on Ca2+, but mitochondria
are important targets of hepatocellular injury
by toxicants that causes oxidative stress,
leading to mitochondrial depolarization,
uncoupling of oxidative phosphorylation,
ATP depletion and cell death (Mehendale
et al. 1994).
5.5.1. Uncoupling at cellular level
Oxidative phosphorylation is the major
mechanism by which aerobic cells produce
ATP using a respiratory assembly located
in the inner mitochondrial membrane (Berg
et al. 2002). In oxidative phosphorylation,
ATP synthesis is coupled to the flow of
electrons towards oxygen by a proton
gradient across the inner mitochondrial
membrane (Figure 4). Electron flow results
in pumping of protons out of the
mitochondrial matrix and generation of
membrane potential. The membrane
potential increases as the electrons flow
down the respiratory chain to oxygen. The
mitochondrial membrane potential across
the inner membrane is the driving force for
phosphorylation since ATP is synthesized
when protons flow back to the matrix
(Fromenty et al. 1990; Brown 1992). The
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Figure 4. In mitochondria, oxidation and ATP synthesis are coupled by transmembrane proton
fluxes (A). When an uncoupling agent is present (B), a protonated form of e.g. DNP transports
protons across the inner mitochondrial membrane, neutralizing the proton gradient.
A. B.
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tight coupling of electron transport and
phosphorylation in mitochondria can be
disrupted by uncoupling agents, which act
as proton carriers that allow protons to flow
into the mitochondrial matrix without
passing through the transmembrane protein
complex that synthesizes ATP from
adenosine diphosphate (ADP) (Terada
1990; Krähenbuhl 2001).  In the presence
of an uncoupling agent, electron transport
proceeds in the normal fashion, but ATP is
not formed since the proton-motive force
across the inner membrane is dissipated. The
rate of oxygen consumption in the absence
of ADP in respiratory substrate-
supplemented mitochondria is low. With
the addition of an uncoupler, the respiratory
rate increases suddenly in a dose-dependent
manner, and at the same time, the
mitochondrial membrane potential
decreases (Terada 1990). The loss of
respiratory control leads to increased oxygen
consumption and to decreased ATP
production as a compensatory function of
the cell. The energy is liberated as heat, which
results in a rise in body temperature (Tainter
and Wood 1934; Kaiser 1964; Terada 1990;
Brown 1992).
The five different metabolic states of
mitochondria have been determined
experimentally by Chance and Williams
(1955) (Table 2) to clarify steady-state levels
during passage of electrons from the
substrate to oxygen. In state 1, mito-
chondria display a slow respiration rate
(Chance and Williams 1955; Hackenbrock
1966). State 2 is characterized by high
concentrations of ADP and respiration is
close to zero. State 3 is the active state of
respiration and phosphorylation (Chance
and Williams 1955). In aerobic state 4, ADP
is totally phosphorylated and the respiration
rate is again low. In state 5, oxygen is lacking
and the ADP level is high. The adding of
uncoupling agents converts this state to state
2 (Chance and Williams 1956). In all states,
mitochondria show the typical
morphological features determined by
Hackenbrock (1966). The level of
respiration in vitro is expressed as a respiratory
Table 2. Metabolic states of mitochondria according to Chance and Williams (1955).
Characteristics Ultrastructural findings
State ADP level Respiration Rate-limiting Mitochondrial morphology
rate substance (Hackenbrock 1966)
1 low slow ADP condensed formation, intramitochondrial
granules
2 high slow substrate highly condensed matrix
3 high fast respiratory chain matrix ↓, intracristal space ↑, small
granules in matrix, inner membrane
foldings
4 low slow ADP condensed formation, intramitochondrial
granules
5 high 0 oxygen
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control ratio (RCR), which is the
relationship between the respiration rate in
state 3 and the respiration rate in state 4. If
the respiration rate in state 4 increases, the
mitochondrial membrane potential
decreases, no ATP is formed and electron
transport and phosphorylation is uncoupled
(Berg et al. 2002).
Various compounds are known to be
uncouplers, but weakly acidic uncoupling
agents are the most potent uncouplers,
speculated to produce uncoupling by their
protonophoric action on the mitochondrial
membrane. Typical examples of uncoupling
agents include salicylic acids, non-steroidal
inflammatory drugs and some local
anaesthetics (Krähenbuhl 2001). As a weak
acid, the uncoupling effect of DNP is
attributable to its protonophoric nature
(Terada 1990). Entacapone and tolcapone
are both structurally related to the known
uncoupling agent DNP. Nissinen et al.
(1997) have shown that tolcapone interacts
with mitochondrial oxygen consumption,
being a more potent uncoupler than DNP
in vitro.
5.5.2. Signs of uncoupling in vivo
Uncoupling agents inducing disruption
between electron transport and phos-
phorylation are generally weakly acidic,
lipid-soluble substances, which enables them
to carry protons across the inner mito-
chondrial membrane (Terada 1990). DNP,
a known uncoupling agent of oxidative
phosphorylation, was used in the 1930s for
weight reduction in humans, until it was
found to be a toxic compound (Figure 3).
Horner et al. (1942) reported that more than
4500 patients used “one capsule three times
a day after meals”. Among these patients,
gastro-intestinal symptoms, such as nausea,
vomiting and loss of appetite, were
common. With long-term use, cutaneous
lesions were frequent and were complicated
by polyneuritis, otitis media and cataracts.
As several patients developed cataracts and
some died due to overdose, the treatment
of obesity with DNP was discontinued in
the 1940s (Horner 1942; Simon 1953).
Most fatal cases have, however, been among
workers in the agricultural industry since
DNP was used as a pesticide and herbicide
(Bidstrup and Payne 1951).
The symptoms of intoxication in man
consist of body temperature exceeding
40ºC, extreme fatigue, profuse sweating and
dehydration, laboured respiration and rapid
onset of rigor mortis after death (Figure 5)
(Perkins 1919; Cutting and Tainter 1933;
Poole and Haining 1934; Horner 1942).
Fatal doses of DNP in the treatment of
obesity have been between 2.66 mg/kg/day
for 14 days and 46 mg twice 7 days apart
(Masserman and Goldsmith 1934; Poole
and Haining 1934). In rats and dogs, oral
treatment with DNP has induced increased
heart rate and abnormal electrocardiographic
readings, elevation of body temperature,
increased oxygen consumption and
increased metabolic rate (Tainter and
Cutting 1933b; Kaiser 1964; Bakke and
Laurence 1965). The cause of death in acute
animal studies is generally considered to be
a result of the pyretic effect of DNP,
produced by an increase in metabolic rate.
Spencer et al. (1948) indicated that rats
treated once by gavage either died within 1-
2 hours or recovered completely. Since
uncoupling of oxidative phosphorylation
induces a reduction in mitochondrial energy
production, leading to usage of glycogen in
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the liver and muscles, instantly occurring
rigor mortis expresses very rapid
consumption of ATP and glycogen from
the skeletal muscle after death (Gracey
1981). In acute DNP poisoning, the
glycogen content in muscles and liver is
diminished (Stoner et al. 1952). Rigor
mortis has been reported to either occur
within 10 minutes of death due to DNP
treatment (Figure 5) (Tainter and Wood
1934) or already be complete at the time of
death (Barnes 1969; Parker 1973).
5.5.3. Uncoupling induced by COMT
inhibitors
Several of the first-generation COMT
inhibitors have been shown to possess
uncoupling properties in vitro. None of
them has been taken into long-term clinical
use. The second-generation COMT
inhibitors have also been reported to express
uncoupling properties in vitro, but in clinical
use, they have not induced any symptoms
Figure 5. Biological effects of uncoupling of oxidative phosphorylation in mitochondria. RCR,
respiratory control ratio.
Hypoxia Respiration  ?
Energy
metabolism  ?
Body temperature  ?
Glycogen  ? Rapid rigor mortis
Mitochondrial
dysfunction
Liver damage
ATP/ADP ?
RCR ?
related to uncoupling in parkinsonian
patients.
Pyrogallol, which structurally resembles
DNP, is reported to be a 4-5 times weaker
uncoupling agent than DNP in vitro (Ross
and Haljasmaa 1964a; Conyers et al. 1968).
It uncouples oxidative phosphorylation in
vitro in isolated mitochondria of both rat
kidney and beef heart (Table 3) (Conyers et
al. 1968). Complete uncoupling was
achieved at a concentration of 1 µM
expressed as the ratio of phosphate esterified
to oxygen consumed. In the same
experiment, complete uncoupling by DNP
was achieved at a concentration of 0.2 µM
(Conyers et al. 1968).
Tropolone and its derivatives reduced
intracellular ATP levels in isolated rat
hepatocytes, and this reduction is associated
with the loss of cell viability (Nakagawa and
Tayama 1998). In isolated rat liver
mitochondria, tropolones also caused a
concentration-dependent increase in the rate
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of state 4 oxygen consumption, thus having
uncoupling properties of oxidative
phosphorylation (Table 3) (Nakagawa and
Tayama 1998). This indicates that the
cytotoxicity induced by tropolones is
associated with ATP depletion via
mitochondrial dysfunction related to
oxidative phosphorylation (Nakagawa and
Tayama 1998).
Propyl gallate and related gallates have
been reported to express uncoupling effects
on mitochondria isolated from rat liver
(Table 3) (Nakagawa and Tayama 1995).
As a sign of uncoupling of oxidative
phosphorylation, propyl gallate induced an
increase in the state 4 oxygen consumption
in rat liver mitochondria as well as a
depletion of ATP in rat hepatocytes
(Nakagawa and Tayama 1995).
Tolcapone has proven to be a potent
uncoupler of oxidative phosphorylation in
vitro at low micromolar concentrations (2.6
µM), while entacapone is a weak uncoupler
at high concentrations only (Table 3)
(Nissinen et al. 1997). Borroni et al. (2001)
reported uncoupling properties of tolcapone
at a similar concentration range (3 µM), and
tolcapone also shows cytotoxic properties
at the same concentration in rat hepatocytes.
5.5.4. COMT inhibition and
uncoupling in relation to protein
binding
Entacapone is 98% and tolcapone 99.9%
bound to plasma proteins (Keränen et al.
1994; Dingemanse et al. 1995). The strong
protein binding is postulated to diminish
the pharmacologically active concentration,
thus also affecting the uncoupling properties
of the drug (Borroni et al. 2001). In
practice, the plasma concentration needed
for clinical response to most of the drugs is
less than the saturated concentration, and
therefore, an equilibrium exists between the
Table 3. Uncoupling and hepatotoxic properties of COMT inhibitors.
COMT Uncoupling effects Liver Central References
inhibitor toxicity effects
Entacapone EC50* 58.0 µM no no Nissinen et al., 1992, 1997; Vaalavirta et al.,
1998
Tropolone intracellular ATP ↓, yes ±0 Ri 1951; Nakagava and Tayama 1995, 1998
state 4 respiration ↑
Pyrogallol 1 mM (complete) no data yes Wylie et al. 1960; Ross and Haljasmaa
1964a; Conyers et al. 1968
Gallates intracellular ATP ↓, yes yes Wylie et al. 1960; Ross and Haljasmaa
state 4 respiration ↑ 1964a; Simpson and Varga 1972; Nakagava
and Tayama 1995
Tolcapone EC50* 2.6 µM yes yes Nissinen et al. 1997; Vaalavirta et al. 1998;
Männistö and Kaakkola, 1999
 *EC50 is the concentration for half of the maximal stimulation of succinate-supported mitochondrial
respiration.
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free and bound drug in plasma. The protein-
bound fraction is stored in the albumin and
the free fraction penetrates such tissues as
the liver, where the drug accumulates if it is
not efficiently metabolized by, e.g.
glucuronidation or sulphation. Despite
extensive protein binding, both inhibitors
have proved to be potent COMT inhibitors
in clinical use (Kaakkola 2000). The
concentration that produces COMT
inhibition is about equal for both inhibitors
(Table 4), but tolcapone expresses
uncoupling properties at a much lower
concentration than entacapone (Nissinen et
al. 1997; Borroni et al. 1999; 2001).
5.6. Pathological findings in
tissues in connection with
uncoupling of oxidative
phosphorylation
5.6.1. Histological findings
Histological findings due to uncoupling of
oxidative phosphorylation in the tissues are
rare. Since the uncoupling of oxidative
phosphorylation is behind the toxic
mechanism of DNP, it has been extensively
used as an experimental example of the
lesions induced by uncoupling. Most of the
experimental studies have been performed
in isolated hepatocytes in vitro or on rat
skeletal muscle in vivo (Hackenbrock 1966;
Buffa et al. 1970; Melmed et al. 1975;
Sahgal et al. 1979; Shah et al. 1982; 1985;
Kawahara et al. 1991; Nakagawa and
Tayama 1995). Only in a few in vivo studies
with DNP have possible histological lesions
been sought; liver tissue in particular has been
studied. After an oral single-dose treatment
of DNP to rats, lesions in the kidney, liver
and spleen have been observed (Spencer et
al. 1948; Arnold et al. 1976). In the kidneys,
tubular necrosis or degeneration is typically
present, in the spleen congestion and
haemosiderosis, and in the liver cloudy
swelling and slight congestion. However, the
liver of dogs treated with single doses of
DNP revealed no histological findings
(doses not given) (Tainter and Cutting
1933b). In skeletal muscle, the only light
microscopy findings, reported in
experimental rat studies with DNP, consist
of subsarcolemmal accumulations of
mitochondria seen as ragged red fibres after
modified Gomori trichrome staining
(Melmed et al. 1975; Sahgal et al. 1979).
The red fibres were confined to oxidative
type I muscle fibres. Large subsarcolemmal
aggregates were verified to be mitochondria
in transmission electron microscopy (TEM)
studies (Sahgal et al. 1979).
In humans, most of the histological
lesions concentrate in the heart and lungs,
and a few liver findings have been reported
due to DNP poisoning. Poole and Haining
(1934) found degeneration of liver cells and
pyknotic nuclei after five days of DNP
treatment at 7 mg/kg. Necrosis of hepato-
Table 4. Concentrations of entacapone and
tolcapone inducing a 50% COMT inhibition
(IC50) and the effective concentration inducing
half of the maximal uncoupling (EC50)
(Nissinen et al. 1997).
COMT inhibitor IC50 (µM) EC50 (µM)
entacapone 0.25 58.0
tolcapone 0.25 2.6
Review of the literature
31
cytes was also identified in a woman who
received DNP for one week (dose not given)
(Lattimore 1934), and “an acute
degenerative hepatitis” with early necrosis
and fatty change was reported in a case of a
man dying in a chemical plant where DNP
was being manufactured (Warthin 1918).
However, the latest histological reports on
humans date back to the 1940s, and in most
cases, no autopsy or histological evaluation
was performed. The liver does not appear
to be a sensitive organ for DNP toxicity in
humans or animals exposed orally, and no
consistent light microscopy liver findings
have been associated with uncoupling of
oxidative phosphorylation induced by DNP
(Research Triangle Institute 1995).
5.6.2. Electron microscopy findings
The ultrastructure of mitochondria in
different experimental metabolic states was
determined in mouse liver by Hackenbrock
in 1966 (Table 5). In state 1, at a slow
respiration rate, the ultrastructure is
characterized by condensed formation with
large intramitochondrial granules (Chance
and Williams 1955; Hackenbrock 1966).
The mitochondria in this state are
indistinguishable from those in state 4. In
state 2, the mitochondria show highly
condensed formation. The volume of their
outer compartment seems to have more
volume than the inner compartment
(Hackenbrock 1966). When oxidative
Table 5. Histological findings in liver and skeletal muscle and TEM findings in mitochondria
after treatment with DNP as an uncoupling agent.
Liver findings References
Histology necrosis of hepatocytes Lattimore 1934; Poole and Haining
cloudy swelling, congestion 1934; Spencer et al. 1948
degeneration of liver cells
TEM, isolated contraction of the inner membrane; Buffa et al. 1970
mitochondria in vitro reduction of the total volume
Skeletal muscle findings
Histology ragged red fibres Melmed et al. 1975
TEM accumulations of mitochondria; Kawahara et al. 1991
swelling; abnormal cristae; rough
endoplasmic reticulum disappeared
accumulations of mitochondria; Sahgal et al. 1979
inclusions; concentric laminar
bodies; vacuoles, dilated sarcotubules
increase in number; swelling; Shah et al. 1982, 1985
inclusions;  concentric laminar
bodies; unfolded cristae; vacuoles,
dilated sarcotubules
unfolded cristae Melmed et al. 1975
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phosphorylation is activated (state 3), the
volume of mitochondrial matrix decreases,
simultaneously with an increase in the
volumes of the outer compartment and
intracristal space. The matrix is associated
with small granules and the inner membrane
forms irregular foldings (Hackenbrock
1966). When uncoupling agents are added,
the morphology shows some similarities
with that of state 2 (Chance and Williams
1956). Although histological findings may
be lacking, typical mitochondrial changes
in TEM studies of isolated rat liver
mitochondria or skeletal muscle cells have
been observed after the treatment with DNP
(Table 5). Buffa et al. (1970) reported
contracted conformation of the inner
mitochondrial sac formed by the inner
membrane and matrix in isolated rat liver
mitochondria. Mitochondrial swelling with
reduced density in the matrix and loss of
cristae have also been observed (Melmed et
al. 1975; Sahgal et al. 1979; Shah et al.
1985; Kawahara et al. 1991). In several cases,
the number of mitochondria was increased,
especially in skeletal muscle under the
sarcolemma, whereas in the perinuclear or
intermyofibrillar region the number of
mitochondria was unaffected (Melmed et
al. 1975; Sahgal et al. 1979; DiMauro et al.
1985; Shah et al. 1985; Kawahara et al.
1991). Large aggregates of mitochondria
were also observed in light microscopy
(Melmed et al. 1975; Sahgal et al. 1979).
Isolated rat liver mitochondria after
incubation with pentachlorophenol,
another uncoupling agent, showed an
increased inner mitochondrial space and a
matrix containing constricted or indistinct
cristae (Weinbach et al. 1967). Mito-
chondria with a ruptured outer membrane
were also seen. However, when rats were
treated intraperitoneally with 60 mg/kg  of
pentachlorophenol, the mitochondria in
liver sections did not differ from those of
control animals (Weinbach et al. 1967).
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Entacapone and tolcapone, two
nitrocatechol-structured COMT inhibitors,
have been used as adjuncts to levodopa in
the treatment of Parkinson’s disease for
several years. Tolcapone has been shown to
induce liver toxicity in clinical use, and three
fatal cases have been reported. Since these
two COMT inhibitors are structurally
related to each other, exploring differences
in their toxicity profiles was warranted.
Furthermore, as some data existed on
tolcapone being an uncoupler of oxidative
6. Aims
phosphorylation, a possible connection
between hepatotoxicity and uncoupling by
COMT inhibition was sought.
These studies were performed to examine:
1. Comparative toxicity profiles of
entacapone and tolcapone in vivo (I, II).
2. Role of uncoupling of oxidative
phosphorylation in these toxicity profiles
in vivo and in vitro (II, III, IV).
3. Effects of total COMT inhibition in
mice in vivo (V).
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7. Materials and methods
7.1. Animals and treatment
In comparative toxicity studies in vivo, (I,
II, III), outbred Crl:CD®BR rats (Sprague-
Dawley origin, supplied by Charles River
Wiga, Sulzfeld, Germany) were used. The
dosing for these studies was conducted in a
semi-barriered, limited-access animal room.
The test suspensions were administered
orally for eight days (I) or two weeks (I, II,
III) to each rat at 24-hour intervals by
gavage using a flexible plastic catheter and a
syringe. In the first study, the doses of
entacapone and tolcapone were 200 and 400
mg/kg/day, and in the second study, 300
and 500 mg/kg/day, with DNP 20 mg/kg/
day serving as a positive reference substance.
Entacapone doses were based on previous
toxicological studies (Entacapone Product
Monograph 1999). Tolcapone doses were
selected according to non-clinical and clinical
exposure data (Tasmar Product Monograph
1997). The dose of DNP was selected to
be the highest dose not inducing mortality
(Spencer et al. 1948). The control animals
received the vehicle 0.5% methyl cellulose.
The commercially available rodent SDS diet
RM1 (E) SQC (Special Diet Services Ltd,
Witham, Essex, England) and tap water
from the public supply, filtered twice, were
available ad libitum. In in vitro studies on
uncoupling properties (II, IV), the same
strain of rat served as a liver donor.
To evaluate the complete lack of the
COMT enzyme in vivo (V), COMT-
deficient mice were used. This knock-out
strain was developed by Gogos et al. (1998)
at Rockefeller University, USA, and
transferred for breeding purposes to the
University of Kuopio, Finland. The
genotype of mice was determined as
described in Huotari et al. (2002). The
commercially available Standard Rodent
Diet R36 (Ewos AB, Sweden) and tap water
from the public supply were available ad
libitum. Animal care was performed
according to the regulations of the Council
of Europe (1990) and the National Research
Council, USA (1996). The study protocols
were approved by the Provincial State Office
of Southern Finland or by the Animal
Ethics Committee of Orion Corporation,
Finland.
7.2. Test substances
Entacapone and tolcapone were synthesized
at Orion Pharma, Espoo, Finland
(Bäckström et al. 1989; Borgylua et al.
1989). The drug substances were identified
by comparing the substances to standards
using infra-red spectra. The impurities in
both entacapone and tolcapone, determined
by high-performance liquid chromato-
graphy (HPLC), were under 0.1%. In
comparative toxicity studies, DNP served
as a positive reference compound. All of
these test substances were suspended in
autoclaved 0.5% methyl cellulose, and the
dosing suspensions were prepared daily
immediately before the oral dosing.
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7.3. Methods in in vivo studies
7.3.1. Clinical signs, mortality, body
weight and organ weights (I, II, V)
The animals were inspected at least once a
day to monitor clinical signs or reactions to
the treatment and mortality. Individual body
weight and body weight gain as well as
body-related organ weights (II, liver; V, liver
and kidneys) were recorded.
7.3.2. Behavioural studies (V)
The activity of all three genotypes was
determined using the ten-channel IRS
Actometer System (custom-designed by L.
Yaviz and E. Koivisto at the University of
Kuopio) for determining the effects of
COMT deficiency on the circadian rhythm
of locomotor activity and on diurnal
rhythm. The measurements were taken at
30-minute consecutive intervals for a total
of 72 hours. An elevated plus-maze test was
performed in mice as described by Handley
and Mithani (1994) with some modifi-
cations (Vasar et al. 1993). During a three-
minute observation session the following
measurements were taken: latency period of
first open part entry, number of attempts
to enter the central square, number of line
crossings in open arms and in the central
square, total time spent in the open part
and open arms, and number of visits to open
and closed arms of plus-maze. Immediately
after the elevated plus-maze test, general
motor activity of each mouse was tested for
two minutes in a dimly illuminated round
box by counting the number of line
crossings and rearings. A forced swimming
test was performed as described by Porsolt
et al. (1977), and active swimming and
floating times were measured.
7.3.3. Body temperature measurements
(I, II, IV)
Rectal body temperature was measured
twice prior to the dosing period to adapt
the animals to this measurement. During
the study the rectal temperature was
measured on several days, once in the
morning immediately before dosing and
one or two hours after the dosing of test
substances or vehicle. A digital thermometer
with a plastic-covered stainless probe was
used.
7.3.4. Haematology and clinical
chemistry (I, II, V)
Blood samples were taken from fasted
animals on the day of terminal necropsy for
haematological (I, V) or clinical chemistry
(I, II, V) analyses. The haematological
analyses were performed using a Sysmex F-
800 Microcellcounter (Toa Medical
Electronics Co. Ltd., Kobe, Japan). In
clinical chemistry determinations, the main
target was the effect of the treatment on
liver function. The analyses were carried out
using a BM/Hitachi 911 E automatic
analyzer (Boehringer Mannheim,
Mannheim, Germany).
7.3.5. Determination of catecholamines
from plasma (V)
Blood samples were collected into tubes with
ethylenediamintetraacetic acid as an anti-
coagulant. The concentrations of NA, A and
DHPG in plasma were determined at the
Clinical Research Services, Turku University,
Turku, Finland, using high-performance
liquid chromatography with colorimetric
electrochemical detection (HPLC-EC), as
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described previously (Scheinin et al. 1991).
7.3.6. Determination of MAO-A and
MAO-B in liver homogenates (V)
The enzyme activity of MAO-A and MAO-
B was determined from mouse liver
homogenates (V) using an enzymatic
radiochemical method. The MAO-A assay
was performed according to Young et al.
(1986), using 14C-hydroxytryptamine
creatinine sulphate as the substrate. MAO-
B activity was determined using 14C-
phenylethylamine hydrochloride as the
substrate, with some modifications to the
two methods described by Keller & al
(1987) and Koulu & al (1989). The results
were expressed as pmol of deaminated
metabolite, 5-hydroxyindoleacetic acid (for
MAO-A) or phenylacetic acid (for MAO-
B), formed per min mg protein. In both
determinations, the protein content was
measured according to Peterson (1977), with
bovine serum as the standard.
7.3.7. Analysis of drug concentrations
in plasma and liver (I, II)
Exposure of the animals to entacapone and
tolcapone was monitored by determining
the plasma and liver concentrations of
entacapone and tolcapone during the dosing
period.
For plasma concentration analysis (I, II),
samples were drawn at several time points
after the dosing. Blood was collected into
lithium-heparinized tubes and kept in ice
until centrifuged. The plasma was separated
and the concentrations of entacapone and
tolcapone were determined using validated
HPLC methods. The limit of detection was
25 ng/ml for both analytes.
For systemic exposure, the area under the
mean plasma concentration (AUC) of
entacapone and tolcapone was calculated
compartment-model independently using
a linear trapezoidal approximation of up to
12 hours (C
tlast
). The area prior to the first
sampling point (10 minutes) was estimated
with no lag time in absorption. The area
beyond the time C
tlast
 was approximated
using a triangular area up to the next
sampling point. The proportion of the
approximated area of the area for the 24-
hour dosing interval (AUC
0-24h
) was a
maximum of  8%.
For liver tissue sampling, the animals were
sacrificed by inhaled carbon dioxide two
hours after the dosing (II). The medial lobe
of the liver was removed, and liver
concentrations of entacapone and tolcapone
were determined by validated HPLC
methods (Timm and Erdin 1992; Wikberg
et al. 1993). The limit of quantification was
50 ng/g of fresh liver tissue.
7.3.8. Histopathology (I, II, III, V)
Tissue samples from the liver were preserved
in 4% buffered formaldehyde. The tissues
were embedded in paraffin wax, sections cut
into 4 µm and stained with haematoxylin
and eosin (H & E). Tissues were examined
under a light microscope.
7.3.9. Electron microscopy (III)
Samples for transmission electron
microscopy were taken from the liver and
skeletal muscle (M. gastrocnemius). Tissue
samples of a maximum size of 1 mm3 were
prefixed in phosphate-buffered (pH 7.2)
2.5% glutaraldehyde. Postfixation was
performed with phosphate-buffered 1%
osmium tetroxide. The thin sections were
studied after dehydration with ethanol,
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embedding in epoxy resin, thin-sectioning
with an ultramicrotome and post-staining
with uranyl acetate and lead citrate.
7.4. Material and methods in
studies at cellular level
7.4.1. Adenosine nucleotides from liver
mitochondria and liver tissue (II)
Mitochondria were isolated immediately
from fresh liver samples of rats by
homogenization and differential centrifu-
gation and used for determination of
adenosine nucleotides. The liver tissue
samples were prepared according to Faupel
et al. (1972).
The adenosine nucleotide [adenosine
monophosphate (AMP), ADP, ATP]
concentrations in mitochondria and liver
homogenates were determined by HPLC
using ultraviolet detection as described by
Carter and Muller (1990). The levels of
adenosine nucleotides were expressed as an
ATP/ADP ratio. The energy status of the
cell was also expressed as an energy charge
[= (½ ADP + ATP) / (AMP + ADP +ATP)].
7.4.2. Mitochondrial oxygen
consumption (II)
The oxygen consumption of isolated
mitochondria was assayed with an oxygen
electrode connected to an amplifier and a
chart recorder (Trounce et al. 1996; Nissinen
et al. 1997) using 5 mM succinate as the
respiration substrate. The rate of oxygen
consumption before (state 4) and after (state
3) adding 2 µl of ADP was recorded and
finally the mitochondria were maximally
uncoupled by adding a known uncoupler,
carbonyl cyanide chlorophenylhydrozone.
The respiratory control ratio [= (oxygen
consumption rate with ADP, state 3)/
(oxygen consumption rate without ADP,
state 4)] (RCR) was calculated. The protein
content of the samples was estimated by the
method of Lowry (1951).
7.4.3. Mitochondrial membrane
potential studies (IV)
Mitochondria from rat liver (IV) were
isolated with differential centrifugation and
prepared as reported earlier (Nissinen et al.
1997). Mitochondrial membrane potential
was measured using a fluorometric method
originally described by Åkerman and
Wikström (1976), and slightly modified by
Kauppinen and Hassinen (1984) and
Fromenty et al. (1990).
Mitochondrial membrane potential was
presented as percentage of membrane
potential in fully energized mitochondria
using the following formula:
Membrane potential (% of maximum)
= (F
max
 – F
n
)/(F
max
 – F
min
) · 100, where
F
max
 = Fluorescence maximum (zero
membrane potential). The reading was
taken at the start of the measurement before
addition of succinate.  F
min
 = Fluorescence
minimum (maximal membrane potential).
The reading was taken after addition of
succinate. F
n
 = Fluorescence after the
addition of the test compound.
7.4.4. Measurement of COMT activity
in protein-binding studies (IV)
COMT activity in vitro was determined
with and without serum proteins using a
soluble COMT preparation from rat liver
as described earlier (Nissinen et al. 1992)
and 3,4-dihydroxybenzoic acid as the
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substrate. The results were expressed as IC
50
values (µM) of the test substances to induce
half of the maximal inhibition of COMT
(%).
7.5. Statistics
Biochemical parameters, clinical chemistry
and body weight related organ weights were
analysed using one-way analysis of variance
in Studies I and II. Log transformation was
applied to assure the assumptions of the
model (normality of residuals). For the
overall tests, a p-value (two-sided) of less
than 0.05 was considered statistically
significant. If statistically significant results
were found, Bonferroni-corrected contrasts
were applied to characterize these results in
more detail. Statistical evaluation of the
body temperature was performed using the
analysis of covariance for unbalanced
repeated measures with one between-factor
(dose groups) and one within-factor (time
points: 0, 2, 26, 50, 74, 98, 122 hours).
The values at the commencement of
treatment (0 hours) were used as a covariate.
In Study V, body weight, organ weights,
body weight related organ weights,
behavioural data, biochemical deter-
minations and clinical chemistry values of
the different COMT knock-out genotypes
were evaluated using two-way analysis of
variance with two between-factors (genotype
and sex). Tukey’s test was used for further
individual comparison in behavioural
studies. Before statistical analysis, all clinical
chemistry parameters were log-transformed
to assure the assumption of normality. For
the overall tests, a p-value of less than 0.05
was considered statistically significant. If the
main effects of genotype or the interactions
between genotype and sex were statistically
significant, pair-wise comparisons were used
to characterize these results in more detail.
Statistical analyses were performed with
SAS® statistical software (version 6.12).
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8. Results
8.1. Comparative toxicity of
entacapone and tolcapone in vivo
8.1.1. Clinical signs, mortality, body
weight and organ weights (I, II, V)
Entacapone was well tolerated in rats; even
at a dose of 600 mg/kg/day up to 15 days,
no clinical signs of toxicity or deaths
occurred. Tolcapone, in turn, induced
clinical symptoms, including tachypnea,
laboured breathing, decreased spontaneous
motor activity and drowsiness, on the fourth
day after treatment of 400 mg/kg/day.
Mortality due to tolcapone treatment was
high, and the tolcapone-treated animals were
terminated because of poor condition at the
latest on the eighth day of treatment. At
necropsy, all of the deaths were considered
to be treatment-related. The reference
substance, DNP, induced no clinical signs
at the dose of 20 mg/kg/day during the 15
days of treatment. Sudden onset of rigor
mortis was observed after tolcapone
treatment already at a dose of 300 mg/kg/
day and DNP of 20 mg/kg/day.
No mortality or clinical signs due to total
COMT inhibition were present in COMT-
deficient mice aged up to one year. The
motor activity of homozygous females was
significantly higher than that of wild-type
mice (p<0.05). In Porsolt’s forced
swimming test, male homozygous mice had
a shorter floating time (p<0.05) (less
depression) than their heterozygous
counterparts, while both heterozygous and
homozygous females had longer floating
times than wild-type females (p<0.05).
Entacapone did not cause changes in
body or liver weight of treated animals.
Tolcapone (300 and 500 mg/kg/day) or
DNP treatment (20 mg/kg/day) resulted in
an increase of about 15% in body weight
related liver weight (p<0.01). The treatment
had no effect on body weight gain of the
animals, except in the high-dose tolcapone
group, where body weight gain was slightly
decreased. At the age of one year, the
homozygous animals of the COMT knock-
out strain had lower body weight than wild-
type animals (p<0.01). Relative kidney
weight was higher in homozygous than in
wild-type animals (p<0.01).
8.1.2. Haematology and clinical
chemistry (I, II, V)
Treatment with entacapone 600 mg/kg/day
or tolcapone 200 mg/kg for 14 days in the
rat induced no changes in haematological
parameters. In COMT knock-out mice, the
parameters did not vary between
homozygous, heterozygous and wild-type
animals.
Clinical chemistry parameters were
unaffected by entacapone treatment (Table
6). However, tolcapone caused a significant
decrease (p<0.001) in protein and globulin
concentrations in serum even at the lower
dose of 300 mg/kg/day. In addition, serum
albumin was decreased  (p<0.001) in
animals treated with tolcapone 500 mg/kg/
day. ALAT was significantly higher in this
dose group than in the control group
(p<0.001). There was also an increase in
SDH for DNP 20 mg/kg/day (p<0.01), and
a marginal increase for tolcapone 300 mg/
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kg/day (p=0.09). The serum glucose
concentration was elevated in the tolcapone
500 mg/kg/day group and in the DNP
group (p<0.001).
In the 12-month-old homozygous
COMT knock-out mice, clinical chemistry
values for APHOS, ALAT, calcium, total
proteins (Prot), albumin (Alb), urea and
glucose (Gluc) were higher than in the wild-
type mouse (V).
8.1.3. Catecholamine plasma levels (V)
The plasma levels of A, NA or DHPG did
not vary between homozygous and wild-
type mice of the COMT knock-out strain.
8.1.4. Activity of MAO-A and MAO-B
in the liver (V)
No statistically significant differences in the
enzyme activities of MAO-A or MAO-B
in the liver tissue were present in different
genotypes of the COMT knock-out mice.
Table 6. Clinical chemistry values (mean ± SD) of the rats treated with entacapone (Enta),
tolcapone (Tolca) or 2,4-dinitrophenol (DNP). N=6, except in Enta groups N=12 and  in Tolca
300 group N=11 (II).
Treatment S-Prot S-Alb S-Glob S-ALAT SDH S-Gluc
mg/kg/day (g/l) (g/l) (g/l) (U/l) (U/l) (mmol/l)
Control 0 66 ± 1.9 33 ± 1.4 34 ± 0.8 57 ± 12.9 15.9 ± 1.5 6.7 ± 1.3
Enta 300 65 ± 3.2 33 ± 1.3 32 ± 2.5 53 ± 10.0 15.5 ± 5.4 6.2 ± 1.0
Enta 500 64 ± 3.7 33 ± 1.3 31 ± 2.9 56 ± 8.1 18.2 ± 5.5 6.9 ± 0.9
Tolca 300 59 ± 2.2*** 31 ± 0.9 28 ± 1.9*** 56 ± 6.8 21.8 ± 5.3 7.1 ± 0.7
Tolca 500 54 ± 3.4*** 28 ± 1.5*** 26 ± 1.9*** 109 ± 9.1*** 16.1 ± 9.4 11.2 ± 2.3***
DNP 20 63 ± 4.2 32 ± 2.1 32 ± 2.3 60 ± 16.2 27.4 ± 10.4** 9.6 ± 1.0***
**  p<0.01,   when compared with the control group, *** p<0.001
S-Prot, serum proteins; S-Alb, serum albumin; S-Glob, serum globulin; S-ALAT, serum ALAT;
S-Gluc, serum glucose
8.1.5. Plasma and liver tissue
concentrations (I, II)
The exposure factors (exposure in animal/
maximum clinical exposure in man) for
entacapone and tolcapone and AUC0-24h
values from mean plasma concentrations
were calculated in relation to the AUC0-24h
reached in humans after maximum clinical
doses of entacapone (10 x 200 mg daily) or
tolcapone (3 x 200 mg daily) (Tasmar
Product Monograph 1997; Entacapone
Product Monograph 1999). The exposure
factor achieved at the highest entacapone
dose level (600 mg/kg/day) was 21. With
tolcapone, an exposure factor of 14 was
achieved at a dose of 400 mg/kg/day.
The concentrations of entacapone and
tolcapone found in liver tissue two hours
after dosing of 300 and 500 mg/kg/day
were comparable (Figure 6). The mean
plasma concentrations of tolcapone were
higher than those achieved after entacapone
treatment in the respective dose groups (300
and 500 mg/kg/day).
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8.1.6. Pathology induced by treatment
with entacapone and tolcapone
8.1.6.1. Histopathological findings (I, II,
III, V)
Histological examination of liver tissue
from entacapone-treated rats at any dose
level did not reveal treatment-related changes
(Figure 7). As a sign of hepatotoxicity,
diffuse centrilobular necrosis at tolcapone
400 mg/kg/day was observed in one out of
five animals (Figure 7). In the rats treated
with the high dose of tolcapone (600 mg/
kg/day), necrotic foci or single cell necrosis
was seen. Centrilobular hypertrophy was
observed in the groups treated with
tolcapone 500 mg/kg/day or DNP 20 mg/
kg/day. Minor necrotic foci or single cell
necrosis was also found in the liver tissue of
rats treated with DNP. All other findings
Figure 6. Concentrations of entacapone (Enta) and tolcapone (Tolca) in rat liver tissue (ng/g)
and in plasma (µg/ml) two hours after dosings at different levels (300 or 500 mg/kg/day)
(mean, SD).
were considered to be normal for this strain
of rats and thus were of no toxicological
significance.
In the COMT knock out-mice, special
emphasis was given to liver, kidneys and
mammary glands in the homozygous and
wild-type animals. The only finding was
decreased midzonal or centrilobular
vacuolization of the liver in homozygous
male mice as compared with the wild-type
animals. Anisocaryosis was observed in both
genotypes. All other findings in different
organs were distributed evenly amongst the
different genotype groups, thus being
normal background data.
8.1.6.2. Electron microscopy findings (III)
Changes occurred in the shape and internal
structure of mitochondria of liver cells in
DNP- and tolcapone-treated rats compared
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Figure 7. Liver of entacapone (left) and tolcapone (right) treated rat. Centrilobular necrosis is
seen in the tolcapone-treated rat liver. Magnification 100x, H&E staining (I).
with entacapone-treated animals (Figure 8).
The DNP- induced changes consisted of
swollen mitochondria, deformed or broken
cristae and reduced matrix density.  With
tolcapone, the matrix density was also
reduced and mitochondria were swollen. In
addition, intracellular oedema was observed
in the liver cells of DNP- and tolcapone-
treated animals. The mitochondria were
similar to each other in the entacapone and
control groups.
In the skeletal muscle, intermyofibrillar
oedema and swelling of transverse (T)-
tubules were seen in both the tolcapone and
DNP groups but more prominently in the
tolcapone group. Contracted sarcomeres,
visualized as shortened I-bands, were also
seen. Mitochondrial swelling and decreased
matrix density were less prominent in
skeletal muscle than in liver tissue, but the
changes were still identifiable in the DNP-
and tolcapone-treated animals. In the
entacapone and control groups, no apparent
findings were made.
8.2. Uncoupling effects related to
entacapone and tolcapone
8.2.1. Signs of uncoupling in vivo
8.2.1.1. Body temperature (I, II, IV)
Entacapone had no effect on body
temperature even at a dose of 600 mg/kg/
day. By contrast, after each dose of tolcapone
(300 mg/kg/day) body temperature
increased within one or two hours from
dosing about one centigrade, the highest
increase being 1.1°C (p<0.01) (Figure 9).
DNP 20 mg/kg/day also induced a
significant increase in rectal body
temperature compared with controls
(1.3°C, p<0.001). The increased tem-
peratures decreased to basal level within 24
hours. A more marked rise in body
temperature up to 41°C preceded the deaths
of six rats treated with tolcapone 600 mg/
kg/day (Figure 10). The combination of
carbidopa and levodopa did not induce any
Results
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changes in body temperature. When
entacapone (400 mg/kg) was added to the
treatment, the temperature decreased
slightly (p<0.05). Tolcapone increased body
temperature at a dose of 50 mg/kg even in
the rats treated with carbidopa/levodopa
(p<0.01).
8.2.2. Signs of uncoupling at cellular
level
8.2.2.1. Adenosine nucleotide
concentrations in liver mitochondria and
liver tissue (II)
Treatment with entacapone did not interfere
with oxidative mitochondrial energy
production (Table 7). Nor did entacapone
induce changes in whole liver ATP synthesis.
Tolcapone treatment of 500 mg/kg/day
reduced both mitochondrial ATP synthesis
and whole liver ATP concentration
(p<0.001). Mitochondrial ATP production
was diminished, as seen in the ATP/ADP
ratio (p<0.01). The energy charge in the
mitochondria and liver tissue (p<0.01) was
also significantly reduced. DNP 20 mg/kg/
day decreased the mitochondrial ATP
concentration, which was reflected as a
reduction in the whole liver ATP
production (p<0.01), and thus, the ATP/
Figure 8. Mitochondrial changes in rat liver treated with DNP 20 mg/kg/day (a) or tolcapone
500 mg/kg/day (b). Mitochondrial swelling and reduced matrix density are seen. Liver from
entacapone-treated (500 mg/kg/day) (c) and control rat (d). M, mitochondria; N, nucleus;
Bar, 500 nm.
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ADP ratio was decreased in the mitochondria
as well as in the whole liver of DNP-treated
rats. There was also a significant reduction
of energy charge in DNP-treated
mitochondria (p<0.001).
8.2.2.2. Mitochondrial oxygen consumption
(II)
Treatment with tolcapone produced a mild
effect on mitochondrial energy production,
reflected in the marginal decrease in the
respiratory control rate (RCR) (p = 0.08).
The RCR ratio of DNP-treated rats was
lowered by only a few percentage points
(Table 7).
8.2.2.3. Mitochondrial membrane
potential (IV)
Entacapone had no effect on mitochondrial
membrane potential when the cumulative
final concentration of entacapone remained
under 100 µM (Figure 11). Tolcapone
added in increasing concentrations gradually
disrupted the membrane potential. The
concentration required to decrease the
membrane potential by 50% was 3.6 µM.
DNP caused a concentration-dependent
decrease of mitochondrial membrane
potential at slightly lower concentrations
than tolcapone. The concentration required
to decrease the membrane potential by 50%
was 1.7 µM. At concentrations of 5 µM or
above, tolcapone and DNP further
suppressed the membrane potential (Figure
11).
8.2.3. COMT activity in relation to
protein binding (IV)
Entacapone and tolcapone inhibited
COMT at equal concentrations (IC
50
 values
of 0.25 µM and 0.24 µM, respectively;
Figure 12), as measured by COMT activity
without preincubation in rat serum.
However, when the compounds were
preincubated in serum for 30 minutes, the
COMT inhibitory activity of entacapone
was somewhat reduced (IC
50
 value 0.54
µM), while that of tolcapone was shifted
to micromolar level (IC
50
 value 2.62 µM).
Figure 9. Mean change in rectal body
temperature of rats measured one or two hours
after entacapone (Enta), tolcapone (Tolca)
and DNP treatment at doses of 300–600 mg/
kg of entacapone and tolcapone and 20 mg/
kg of DNP. Bars represent SD, ** p<0.01,
*** p<0.001.
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Figure 10. Rectal body temperature after tolcapone treatment of individual rats that died at
various time points during the study. The temperature was measured just before death. Doses
were tolcapone 400 or 600 mg/kg/day tolcapone. †  = time of death (I).
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Table 7. Adenosine nucleotide ratios; mitochondrial and liver tissue values (mean ± SD) of the rats
treated with entacapone (Enta), tolcapone (Tolca) or 2,4-dinitrophenol (DNP). N=6 (II).
Treatment Mitochondria Liver tissue
 mg/kg/day ATP/ADP EC1 ATP/ADP EC1 RCR2
Control 0 3.12 ± 0.36 0.83 ± 0.02 3.07 ± 0.54 0.83 ± 0.04 5.01 ± 0.49
Enta 500 2.84 ± 0.44 0.81 ± 0.04 2.78 ± 0.43 0.81 ± 0.03 5.45 ± 0.27
DNP 20 1.46 ± 0.35*** 0.63 ± 0.07*** 2.12 ± 0.54 0.74 ± 0.08** 4.87 ± 0.37
Control3 0 3.55 ± 0.73 0.85 ± 0.04 3.79 ± 0.46 0.86 ± 0.02 5.37 ± 0.61
Tolca 500 1.88 ± 0.69** 0.69 ± 0.10** 2.44 ± 0.57*** 0.76 ± 0.07** 4.85 ± 0.32§
1 EC = energy charge
2 RCR = Respiratory Control Ratio
3 Control for the group treated with tolcapone 500 mg/kg/day
* * p<0.01,  when compared with the control group); ***  p<0.001
§ p = 0.08
46
Concentration (µM)
1 1,7 3,6 10 100
M
em
br
an
e 
po
te
nt
ia
l (
%
)
0
20
40
60
80
100
EC50
tolcapone
2,4-dinitrophenol
entacapone
Figure 11. Concentration dependency for the effect of entacapone, tolcapone or 2,4-
dinitrophenol on mitochondrial membrane potential (% of maximum). Mitochondria were
isolated from rat liver. N=1-5. EC
50
 is the concentration which induces a 50% inhibition of
membrane potential (IV).
Figure 12. Effect of addition of rat serum on COMT inhibition activity (%) of entacapone and
tolcapone using soluble COMT from rat liver. N=3. IC
50
 indicates the concentration at which
the COMT inhibition is 50% of the maximum (IV).
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Table 8. Summary of the signs in relation to hepatotoxicity and oxidative phosphorylation in vivo
and in vitro in rats after treatment with entacapone, tolcapone or 2,4-dinitrophenol (DNP).
Finding Entacapone Tolcapone DNP
In vivo
Mortality — ↑ —
Relative liver weight — ↑ ↑
Liver enzymes — ↑ ↑
Serum proteins — ↓ —
Body temperature — ↑ ↑
Onset of rigor mortis — < 10 min < 10 min
Liver histology — necrosis necrotic foci
Liver mitochondria — swelling; deformed swelling;deformed
cristae; matrix density ↓ cristae; matrix density ↓
Skeletal muscle — intermyofibrillar oedema intermyofibrillar oedema
ultrastructure contracted sarcomeres contracted sarcomeres
Skeletal muscle — swelling; matrix density ↓ swelling; matrix density ↓
mitochondria
At cellular level
ATP/ADP mitochondria — ↓ ↓
EC1  liver tissue — ↓ ↓
RCR2  mitochondria — (↓) —
Mitochondrial membrane — ↓ ↓
potential
1 EC = energy charge
2 RCR = respiratory control ratio
(↑/ ↓) marginal increase/decrease
— not affected
8.3. Summary of the results in
vivo and in vitro
Table 8 summarizes the results of in vivo
and in vitro studies.
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9.1. Comparative toxicology of
entacapone and tolcapone in vivo
9.1.1. Clinical signs and mortality
COMT inhibition has been postulated to
be toxic, inducing hepatotoxicity and
leading to further complications in clinical
use (Rivest et al. 1999; Olanow 2000). Since
entacapone and tolcapone are structurally
related COMT inhibitors, they have been
speculated to have similar toxic effects. Both
have undergone extensive non-clinical
toxicity testing in several animal species, and
no toxicity has been reported, even with
high-dose treatment (Tasmar Product
Monograph 1997; Entacapone Product
Monograph 1999). Despite the safety
studies and clinical trials, several cases of
hepatotoxicity due to clinical treatment with
tolcapone have emerged (Assal et al. 1998;
Mayoral et al. 1999; Olanow 2000).
The toxicity of entacapone and tolcapone
proved to be different in rats receiving high
oral doses (I, II). Entacapone was well
tolerated up to 15 days at high oral doses
with no signs of toxicity. However, the first
signs of toxicity after tolcapone treatment
were expressed on the third day, and
mortality increased during the next eight
days of treatment such that the remaining
animals in the tolcapone-treated groups
were euthanized. The clinical symptoms in
rats consisted of laboured breathing,
decreased spontaneous motor activity and
drowsiness.  The symptoms usually faded
away after two to three hours from dosing,
although some of the rats died quite
9. Discussion
suddenly. The symptoms after tolcapone
treatment are consistent with those in
Spencer et al. (1948), who reported that rats
after oral dosing of 30 mg/kg or more of
DNP either died within one to two hours
or recovered completely. This is also in
accordance with a mouse study on DNP,
where peak concentrations of DNP were
reported to be reached within one hour in
plasma and within two hours in liver tissue
after oral dosing (Robert 1986). In Study
II, the selected dose of DNP (20 mg/kg/
day) was approximated to be the highest
dose not to induce any mortality or clinical
symptoms (Spencer et al. 1948). The doses
of entacapone were selected according to
previous toxicity studies (Entacapone
Product Monograph 1999), while
tolcapone doses were based on non-clinical
and clinical exposure data (Tasmar Product
Monograph 1997). In these earlier
toxicological profile studies, tolcapone had
proved to be well tolerated (Eckhardt et al.
1996; Schläppi et al. 1996a; 1996b; Tasmar
Product Monograph 1997), with only a
few clinical symptoms, consisting of
respiratory difficulties in connection with
premature deaths or some female rats lying
on the side for several minutes after the
dosing (300 mg/kg/day), reported (Tasmar
Product Monograph 1997). In the four-
week oral toxicity study in rats, three animals
died within 15 to 60 minutes after dosing
(Schläppi et al. 1996a). In one case, the
cause of death was speculated to be due to
exaggerated pharmacological activity or
hypoxia (Schläppi et al. 1996a). However,
the conditions in non-clinical long-term
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toxicity studies were different from those
in Studies I and II since in the former studies
tolcapone had been administered to rats as
a feed mixture, and in dietary studies, the
exposure remains lower and no high peak
plasma concentrations occur. Thus, the high
mortality following tolcapone treatment in
Studies I and II is considered to be related
to the treatment.
In the behavioural studies with COMT
knock-out mice, the differences between the
genotypes were marginal and always less
than differences between the sexes. Thus,
reduced or total lack of COMT enzyme
activity does not appear to be associated with
any clinical symptoms or changed
behaviour.
9.1.2. Hepatotoxic properties of
entacapone and tolcapone
Drug-induced hepatotoxicity is the leading
reason for withdrawal of a drug from the
market (Lee 1995; Lasser et al. 2002;
Thomas 2002). Hepatotoxicity is also the
most serous problem in tolcapone-induced
toxicity in clinical use (Assal et al. 1998;
Mayoral et al. 1999; Olanow 2000;
Watkins 2000). Three fatal cases due to
tolcapone treatment have been reported, and
two of them were characterized by hepatic
necrosis (Assal et al. 1998; Olanow 2000).
The first indication of drug-induced
hepatotoxicity is the rise in clinical chemistry
parameters e.g. ALAT (Watkins 2000). In
laboratory animals, SDH is the second
choice marker of hepatotoxicity (Loeb and
Quimby 1999). Tolcapone induced a
twofold elevation in rat ALAT values as
compared with the control group, indicating
a mild hepatocellular disturbance (II). In
addition, the serum protein values were
decreased significantly in tolcapone-treated
rats, signalling the diminished capacity of
the liver to synthesize proteins. In DNP
treatment, SDH was significantly increased.
Robert (1986) has reported treatment of
mice with a single dose of DNP 22.5 mg/
kg, where plasma ALAT activity was not
significantly different from the control
levels; SDH was not measured. A positive
correlation between hepatocellular damage
and an increase of serum ALAT and SDH
activities in the rat has been observed earlier
(Travlos et al. 1996), with ALAT values also
reflecting the severity of hepatocellular
necrosis (Balazs et al. 1961). Liver cell
necrosis and hypertrophy in animal studies
are reported to be associated with increased
serum concentrations of either SDH or
ALAT in about 40-58% of the cases
(Travlos et al. 1996). The elevations in
ALAT and SDH activities were reflected in
liver histology as necrotic foci and single cell
necrosis in both tolcapone- and DNP-
treated rats (I, II). Hepatocellular hyper-
trophy was also observed, with increased
liver weight of about 15% (II). Electron
microscopy examination of liver cells of
tolcapone- and DNP-treated rats revealed
swelling of mitochondria, deformation of
cristae and reduced matrix density (III).
These findings are consistent with those in
a tolcapone-treated patient dying from
fulminant drug-induced hepatitis (Assal et
al. 1998; Spahr et al. 2000). Electron micro-
scopy findings showed mitochondrial
swelling with reduced density in the matrix
and loss of cristae (McCaul et al. 1986;
Spahr et al. 2000).
Tolcapone is reported to induce slight to
moderate hepatocellular hypertrophy in mice
after 18 months of treatment (Olanow
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2000), but in a four-week study in the rat,
while liver weight increased 10%, no
hypertrophy was observed (Schläppi et al.
1996a). Hypertrophy is usually regarded as
an adaptive response to drug-induced
microsomal enzyme induction in the liver,
although in some cases, this enhanced
metabolism may give rise to long-term
toxicity (Greaves 1990).
Centrilobular necrosis was observed in
one rat treated with tolcapone for three days.
Since the peak serum enzyme rise usually
occurs at about 24 hours after the dosing,
and induced liver damage, depending on the
hepatotoxic agent, the enzyme value and the
degree of histological necrosis do not
correlate with each other to the same extent
later (Dixon et al. 1975). By two to three
weeks from the beginning of treatment,
serum SDH is more predictive in treatment-
related rat liver histopathological lesions
than serum ALAT (Travlos et al. 1996). In
non-clinical toxicity testing of tolcapone,
no elevations of serum enzyme levels in rats
or dogs have been reported (Schläppi et al.
1996a; 1996b; 1996c; Tasmar Product
Monograph 1997). However, total protein
values in female rats were significantly
decreased after four weeks’ oral treatment
(400/300 mg/kg/day) (Schläppi et al.
1996a), which is consistent with the
findings in Study II. By contrast, entacapone
did not induce elevation in the liver enzymes
or protein values in rats, even at the high
doses used.
Centrilobular necrosis in liver tissue is the
most frequent form of drug-induced
hepatocytic necrosis (Haschek et al. 2002).
This was also observed in a liver biopsy of a
tolcapone-treated patient (Assal et al. 1998).
The patient died of hepatic failure, and
histological findings in the liver supported
treatment-related hepatotoxicity.
Centrilobular necrosis follows circulatory
shock, as oxygen is depleted by the passage
of blood through the periportal areas. Since
centrilobular hepatocytes have a much
higher content of drug-metabolizing
enzymes than periportal hepatocytes, the
toxic response takes place in the centrilobular
area. Necrosis can occur within minutes of
a toxic insult and is usually associated with
severe metabolic disturbances. The onset of
cell death is characterized by breakdown of
the plasma membrane permeability barrier,
which leads to loss of metabolic inter-
mediates and leakage of liver enzymes into
the circulation (Mehendale et al. 1994).
When the metabolic system is disrupted,
the concentration of toxic substances
increases in centrilobular areas, leading to
degeneration and further necrosis of
hepatocytes. Even if destruction of tissue is
extensive, inflammatory cell infiltration may
still be limited. The necrosis begins to
regenerate within 24 hours, and within one
week can be totally healed (Haschek et al.
2002).
The specific mechanism of drug-induced
hepatotoxicity remains unknown. It might
be an idiosyncratic reaction of partly genetic
background or may be associated with
mitochondrial toxicity (Dossing and Sonne
1993; Acuna et al. 2001). With few
exceptions, hepatotoxic reactions induced
by drugs are not a dose-related phenomenon
(Lee 1995; Watkins 2000). However, in
clinical use, tolcapone did induce a clear
dose-response effect with respect to liver
enzyme elevation (Mayoral et al. 1999;
Olanow 2000; Watkins 2000). Gasser and
Smit (2001) have also reported that 5.7%
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of patients (N=3848) receiving 200 mg
three times daily of tolcapone experienced
liver function abnormalities. Moreover, in
all three fatal cases due to hepatotoxicity after
tolcapone treatment clinically, serum ALAT
was raised to more than three times the ULN
(Assal et al. 1998; Mayoral et al. 1999;
Olanow 2000). Entacapone, by contrast, has
not induced severe hepatotoxicity in clinical
use (Watkins 2000). The mechanism behind
tolcapone-induced hepatotoxicity may be
associated with the lipid solubility and the
metabolism of tolcapone, which differ from
those of entacapone (Nissinen et al. 1992;
Wikberg et al. 1993; Dingemanse et al.
1995; Dingemanse 1997). If a drug is not
efficiently metabolized, e.g. by glucu-
ronidation or sulphation after dissociating
from serum proteins, it can accumulate in
such tissues as the liver. Thus, intracellular
concentrations of tolcapone might be
increased in the liver tissue of patients whose
glucuronidation rate is poor, which is
reflected in liver function abnormalities.
Some parkinsonian patients, for instance,
have a deficiency in mitochondrial
respiratory chain function that affects the
first enzyme complex involved in oxidative
phosphorylation (Schapira 1994; Schapira
2001). This genetically determined complex
I defect may be exacerbated by DA, which
increases free radical formation and may
damage the mitochondrial respiratory chain
function. The dysfunction can reduce ATP
synthesis, leaving the cell with inadequate
energy (Schapira 2001). If treatment with a
COMT inhibitor results in uncoupling of
oxidative phosphorylation, these patients are
then more vulnerable to toxic effects
(Schapira 2001; Orth and Schapira 2002).
Homozygous COMT knock-out mice
showed slightly higher levels of certain
clinical chemistry values as well as
hyperglycemia associated with lower body
weight than wild-type mice (V). It could
be assumed that in these homozygous mice
the levels of catecholamines are higher than
in wild-type mice, leading to a mild
catabolic condition reflected as
hypermetabolism, hyperglycemia and a
lower body weight. Since endogenous A and
NA are capable of potentiating the
hepatotoxicity induced by several drugs in
the rat (Roberts et al. 1997), the total
COMT inhibition with elevated
catecholamines in plasma could be expressed
as liver toxicity in the COMT knock-out
mouse.  However, a complete lack of
COMT activity in mice did not cause
significant liver problems (V). Experi-
mentally, in rabbits as well as in clinical use,
tolcapone has been shown to increase
catecholamine plasma levels, and one patient
was reported to simultaneously have had
elevated liver enzymes (Garrido et al. 1994;
Rojo et al. 2001). However, the levels of
catecholamines in plasma of knock-out
mice were not significantly increased despite
high DHPG levels, nor did the activities of
the two MAO isoenzymes in the liver (V)
differ between the genotypes. There were
no increases in general motor activity or in
the levels of anxiety and depression in the
mice lacking COMT, supporting the view
that there was no enhanced catechol-
aminergic tone in these animals. To be a class
effect of COMT inhibitors or COMT
inhibition, liver toxicity should be induced
by both entacapone and tolcapone in
clinical use due to the close structural
relationship of these agents.  Liver toxicity
should also be expressed as histopathology
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in COMT-deficient mice (Watkins 2000).
Since no toxicity as histopathology or
elevated liver enzyme values were noted after
entacapone treatment or in homozygous
COMT knock-out mice, COMT
inhibition as such does not appear to cause
significant liver toxicity.
9.1.3. Exposure of animals to
entacapone and tolcapone
The plasma concentration of tolcapone two
hours after the dosing was clearly higher
than that of entacapone (I, II). Moreover,
in clinical use, a peak concentration of
approximately 6 µg/ml is reached after an
oral tolcapone dose of 200 mg, while after
an equal dose of entacapone the peak
concentration is 1.8 µg/ml (Table 9)
(Keränen et al. 1994; Dingemanse et al.
1995). Thus, the AUC of tolcapone at the
maximal recommended dosage in man is
much higher than that of entacapone (for
tolcapone 75 h•µg/ml, dosage 3 x 200 mg/
day; for entacapone 20 h•µg/ml, dosage 10
x 200 mg/day). However, the calculated
exposure factor in entacapone- and
tolcapone-treated animals was 21 and 14,
respectively. At the same time point, the
concentrations of entacapone and tolcapone
were equally high in liver tissue, indicating
that both compounds can penetrate the liver
similarly although highly bound to plasma
proteins (Dingemanse 1997). At com-
parable liver concentrations, entacapone
caused no toxic effects in rats, while
tolcapone did induce toxic signs in vivo.
9.2. Uncoupling effects related to
entacapone and tolcapone
9.2.1. Signs of uncoupling in vivo
The effect of entacapone and tolcapone on
the body temperature of rats measured one
or two hours after the dosing was clearly
different (I, II). Entacapone caused no
elevation, while both tolcapone and DNP
treatments induced a significant increase in
body temperature of rats. Furthermore,
Table 9. In vitro concentrations of entacapone and tolcapone inducing 50% COMT inhibition
(IC50) and in vivo (clinical) data on peak plasma concentrations (Cmax) after a single dose of 200
mg of entacapone or tolcapone, and the concentrations in the liver tissue in rats in vivo (dose 500
mg/kg/day).
Compound COMT inhibition in vitro Clinical data Liver tissue
concentration
IC50 (µM) IC50 (µM) Cmax Cmax (µM) Cmax (µM)* (ng/g
without serum with serum (µg/ml) total unbound wet tissue)
proteins proteins
Entacapone 0.24 0.54 1.8   5.9 0.118 22.9 ± 2.4
Tolcapone 0.25 2.62 6.3 23.0 0.023 19.1 ± 3.1
*calculated from the clinical data as unbound to serum proteins
(Keränen et al. 1994; Dingemanse et al. 1995)
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some of the premature deaths of animals
after tolcapone treatment were preceded by
body temperature increasing up to 41ºC.
In several cases of DNP poisoning in clinical
use, body temperature has been shown to
be markedly increased (Horner 1942). In
the presence of levodopa and carbidopa (IV),
tolcapone induced an elevation of body
temperature after a single oral dose, while
entacapone had a slight decreasing effect on
temperature. Dopamine agonists are known
to induce a decrease in body temperature
through stimulation of dopamine D
2
receptors (Cox and Tha 1975; Faunt and
Crocker 1987). Since concomitant dosing
of COMT inhibitors with DDC inhibitors
increases the bioavailability of levodopa, the
decrease in body temperature after
entacapone treatment may be due to a
higher DA concentration in the brain. As
levodopa treatment has been reported not
to interfere with mitochondrial respiration
in rat skeletal muscle (Dagani et al. 1991),
the mechanism by which tolcapone induces
a rise in body temperature is apparently
unrelated to DA concentration but may be
a result of uncoupling of oxidative
phosphorylation.
Rigor mortis was not observed in
entacapone-treated animals during the 20-
to 30 minute necropsy; however, it was seen
immediately after death in tolcapone- and
DNP-treated rats (I, II). The rapid onset of
rigor mortis has also been reported in
previous non-clinical testing of tolcapone
and toxicity studies with DNP in the rat
(Spencer et al. 1948; Eckhardt et al. 1996;
Schläppi et al. 1996b). Instantly occurring
rigor mortis indicates very rapid usage of
ATP and glycogen from the skeletal muscle
cells upon the death (Gracey 1981). After
administering uncoupling agents, the
amount of ATP is already low before death,
and therefore, rigor mortis should occur at
the time of death or directly after it. In
skeletal muscles, intermyofibrillar oedema
together with prominent contraction of
sarcomeres in the tolcapone groups
resembles findings during the early changes
of rigor mortis (Collan and Salmenperä
1976; Kobayashi et al. 1999). Melmed et
al. (1975) have postulated that gross
morphological changes in mitochondria
only occur when the concentration of an
uncoupler in the cell is very high. The
situation in vivo differs from that in vitro
since in in vivo studies the concentration of
an uncoupling agent in the liver or skeletal
muscle cell after one dose may not reach
the same concentrations as in isolated
mitochondria in an incubation medium in
vitro. To induce alterations in the mito-
chondrial morphology in vivo, the test
substance should be administered repeatedly
and over a longer period of time to allow it
to accumulate in the tissue and cell. During
the several days of dosing in Study III the
mitochondrial changes due to uncoupling
should also have become apparent. In the
liver cells, swelling of mitochondria,
deformation of cristae and reduced matrix
density were observed in DNP- and
tolcapone-treated rats, and these findings are
comparable with those reported by Spahr
et al. (2000) in a clinical case report after
tolcapone treatment.
9.2.2. Signs of uncoupling at cellular
level
The liver mitochondrial ATP/ADP ratio
was unaffected by treatment with high oral
doses of entacapone (II). The ratio decreased
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significantly after treatment with tolcapone
or DNP, indicating uncoupling of oxidative
phosphorylation at the cellular level
(Cutting and Tainter 1933; Kaiser 1964;
Bakke and Laurence 1965). Both tolcapone
and DNP have earlier been shown to be
potent uncouplers in vitro in isolated rat liver
mitochondria (Loomis and Lipmann 1948;
Terada 1990; Nissinen et al. 1997). Study
II demonstrated that tolcapone has the
potential to interfere with oxidative energy
metabolism in the liver in vivo. The
hampered oxidative ATP production was
also seen in the lowered energy charge in
the tolcapone-treated rat liver mitochondria
and at the level of the whole liver tissue.
Decreased ATP production leads to increased
oxygen consumption as a compensatory
function of the cell and cell death may occur.
In isolated rat liver mitochondria, both
tolcapone and DNP had also a direct
disruptive effect on mitochondrial
membrane potential at the same con-
centration range, EC
50
 being lower than 5
µM (IV). Entacapone did not have any
effect on membrane potential at
concentrations lower than 100 µM. Thus,
entacapone has no influence on cellular
respiration or mitochondrial oxygen
consumption until concentrations are
beyond the physiological, and does not
uncouple oxidative phosphorylation by
disrupting the mitochondrial membrane
potential. EC
50
 for stimulation of succinate-
supported mitochondrial respiration of
tolcapone has earlier been reported to be 2.6
µM, which is in the same concentration
range as the concentration for disruption of
membrane potential in Study IV (Nissinen
et al. 1997). These results are also consistent
with those of Borroni et al. (2001), who
reported that the lowest effective dose of
tolcapone to induce a concentration-
dependent increase in respiration rate is
1 µM. At a concentration range of 1 to 300
µM, tolcapone further reduced the
mitochondrial membrane potential in a
dose-dependent fashion. When uncoupling
of oxidative phosphorylation decreases the
amount of ATP, the synthesis of ATP and
ADP from glucose in the liver is diminished
and energy is generated mainly from
glycolysis. Increased liver pyruvate induces
gluconeogenesis, which is reflected as an
elevation of short duration in serum glucose
concentration (Berg et al. 2002), as was also
shown in the DNP- and tolcapone-treated
rats (II). The reason for the greater potential
of tolcapone than entacapone to cause
uncoupling might relate to tolcapone’s lipid
solubility (Dingemanse 1997). Since
tolcapone is a more lipophilic compound,
it more easily penetrates the cell membrane
and crosses the mitochondrial bilayer than
the less lipid-soluble entacapone, inducing
a disruption in membrane potential.
Borroni et al. (2001) have speculated
about the discrepancy between in vitro and
in vivo findings regarding uncoupling. They
assumed that because the free fraction of a
drug is diminished by extensive protein
binding in vivo, the uncoupling effect of
both tolcapone and DNP is counteracted
(Borroni et al. 1999; 2001). As entacapone
is 98% and tolcapone 99.9% bound to
plasma proteins in vitro, the effective free
concentrations would be 2% and 0.1%,
respectively (Dingemanse 1997). However,
entacapone and tolcapone are equally potent
COMT inhibitors in vitro (IV), with an
IC
50
 value of ca. 0.25 µM, when a rat liver
soluble COMT preparation without added
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rat serum is used. After adding the serum
to the incubation mixture, a tenfold
concentration of tolcapone is needed to
achieve a similar IC
50
 value of COMT
inhibition, whereas only twice as much
entacapone is needed for a 50% COMT
inhibition in the presence of serum (Table
9). However, in clinical use, both inhibitors
have proved to be potent COMT inhibitors
despite extensive protein binding (Kaakkola
2000). If protein binding noticeably
decreases the pharmacological activity of the
compounds in vivo, the unbound concen-
tration of entacapone and tolcapone in
clinical use should be twice and ten times as
high, respectively, to achieve effective
COMT inhibition (Table 8), which
contradicts the results of Borroni et al.
(2001).
Findings in vitro and in vivo are not
directly comparable since in vitro the
reactions are carried out over a few minutes,
whereas in vivo the drug is present for hours.
Due to the equilibrium between the protein-
bound and free fractions of a drug in
plasma, the free fraction penetrates tissues
and can act as a potential protonophoric
uncoupler if it is not effectively further
metabolized. However, the liver
concentrations of both tolcapone and
entacapone are equally high after oral dosing
to rats (II), indicating that both compounds
can penetrate the liver despite being highly
bound to plasma proteins. Thus, the
extensive binding of a drug to serum
proteins does not directly affect tissue
concentrations or prevent uncoupling of
oxidative phosphorylation in vivo.
The dissimilarities in the hepatic safety
of entacapone and tolcapone may be due to
different metabolic routes as well as the
lipophilicity of the two compounds. As a
more lipophilic compound, tolcapone
readily crosses mitochondrial membranes.
The only significant metabolic route for
entacapone is glucuronidation, whereas
tolcapone also undergoes oxidation and
methylation. Uncoupling of oxidative
phosphorylation may have a role in the
hepatotoxicity caused by tolcapone
treatment, as uncoupling properties
comparable with those of DNP are
expressed by tolcapone both in vivo and in
vitro.
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10. Conclusions
The non-clinical safety of entacapone and
tolcapone, two nitrocatechol-structured
COMT inhibitors designed as adjuncts to
levodopa treatment of Parkinson’s disease,
was compared in vivo and in vitro.
After repeated high oral doses to rats,
entacapone did not cause toxicity, while
equal doses of tolcapone induced severe
toxic signs. These signs were comparable
with those induced by DNP, an uncoupler
of oxidative phophorylation. Histo-
pathological findings after tolcapone
treatement were of the same type as in
DNP-treated rats, including changes to the
liver and the ultrastructure of liver and
skeletal muscle mitochondria. Moreover,
tolcapone was shown to cause uncoupling
of respiration on mitochondrial membranes
in vitro. Taken together, uncoupling of
oxidative phophorylation may have a role
in the hepatotoxicity caused by tolcapone.
COMT inhibition as such did not induce
toxic signs in mice lacking COMT activity,
nor did it cause any liver problems. The
results indicate that toxicity induced by one
COMT inhibitor cannot be generalized to
all agents in the same class.
Conclusions
57
The present study was carried out at the
Department of Basic Veterinary Sciences,
Section of Veterinary Pathology of the
Faculty of Veterinary Medicine, University
of Helsinki, and at Orion Pharma, Research
Centre, Espoo.
I wish to express my deepest gratitude to:
Professor Antti Sukura, DVM, PhD, for
his support, generous advice and discussions
over these trying years. His never-failing
enthusiasm, humour and good mood
encouraged me to keep going.
Docent Erkki Nissinen, PhD, for his
continuous support and encouragement as
well as his sharp but valuable criticism
throughout this work. His door was always
open.
Docent Esa Heinonen, MD, PhD, for
providing the idea of this thesis and for
guidance, especially during the first years.
He also taught me how to write scientific
publications, even though it sometimes took
numerous versions over a period of months.
 Professor Anthony Schapira, DSc, MD,
FRCP, FMedSci, and Professor Raimo
Tuominen, MD, PhD, for constructive
criticism which is largely responsible for the
text’s final form.
My colleague Leena Sopanen, MSc, for
ideas and new ways of thinking about
problems and for cheering me up on rainy
days.
My colleague Arja Vuorela, MSc, for
teaching me everything I know about
pharmacokinetics. I hope that I’ve gained
at least a small part of her enthusiasm and
11. Acknowledgements
knowledge about kinetics.
Professor Pekka T. Männistö, MD, PhD,
for initiating the COMT project and for
pushing me forward every now and then.
My colleagues Docent Inge-Britt Lindén,
PhD, and Malla Toivonen, MSc, for
valuable comments on the manuscript.
Co-workers Marko Huotari, PhD, Anita
Koponen, MSc, Docent Kari Lounatmaa,
PhD, Kai Penttilä, PhD and Leila Vaalavirta,
MD, PhD for contribution during the
different phases of this thesis.
Jarmo Pystynen, MSc, for providing me
with valuable information on nitrocatechols
and molecular structures.
Pasi Hakulinen, BSc, for helping me
with statistics and for advice on how to
apply the methods to non-clinical work.
Pia Friman for helping me with figures,
and Helena Helander and Olli Louhimo for
efficiently providing me with articles.
Ulla Hirvensalo, MSc, Aino Pippuri,
MSc, and Heikki Brandt, MD, for our
meetings on Wednesday mornings and for
discussions that went beyond science and
work. Without Aino, this thesis would not
have come reality, as she is the person who
synthesized entacapone.
The whole staff at the Department of
Toxicology, Orion Pharma, as well as my
colleagues on the second floor of the
Research Centre. It has been a pleasure to
work with you.
Carol Ann Pelli, HonBSc, for editing the
English of the manuscript and for her
kindness in conforming to my time
schedules.
My dear husband Jussi, MD, PhD, for
Acknowledgements
58
preparing the layout of this thesis, and Armi
and Lassi for just being there. Thank you
all three so much. You brought cheer to hard
days with music played on the piano or
accordion. Without your support, this work
would never have been completed.
The financial support of Orion Pharma
and the Finnish Academy is greatly
appreciated.
Espoo, April 2003
Acknowledgements
59
Acuna, G., Foernzler, F., Leong, D., Gasser,
R., Dorflinger, E., Borroni, E., To, Z.,
Smit, R., Rabbia, M., Thompson, A.,
Hashimoto, L. and Lindpaintner, K.
(2001) Genetic susceptibility to
tolcapone-induced liver injury,
Parkinsonism Relat Disord, 7 (Suppl):
S25.
Agathopoulos, A., Nicolopoulos, D.,
Matsaniotis, N. and papdatos, C. (1971)
Biochemical changes of catechol-O-
methyltransferase during development of
human liver, Pediatrics, 47: 125-128.
Åkerman, K. and Wikström, M. (1976)
Safranine as a probe of the mitochondrial
membrane potential, FEBS Lett, 68: 191-
197.
Amin, A.M., Creveling, C.R. and Lowe,
M.C. (1983) Immunohistochemical
localization of catechol methyltransferase
in normal and cancerous breast tissues of
mice and rats, J Natl Cancer Inst, 70: 337-
339.
Angel, A. and Rodgers, K.J. (1968)
Convulsant action of polyphenols, Nature
(London), 217: 84-85.
Aprille, J.R. and Malamud, D.F. (1975)
Catechol-O-methyl transferase in mouse
liver plasma membranes, Biochem
Biophys Res Comm, 64: 1293-1302.
Arnold, L., Collins, C. and Starmer, G.A.
(1976) Studies on the modification of
renal lesions due to aspirin and
oxyphenbutazone in the rat and the effects
on the kidney of 2,4-dinitrophenol,
Pathology, 8: 179-184.
Assal, F., Spahr, L., Hadengue, A., Rubbici-
Brandt, L. and Burkhard, P. (1998)
Tolcapone and fulminant hepatitis, Lancet,
352: 958.
12. References
Assicot, M. and Bohuon, C. (1971) Presence
of two distinct catechol-O-
methyltransferase activities in red blood
cells, Biochimie, 53: 871-874.
Assicot, M., Contesso, G. and Bohuon, C.
(1977) Catechol-O-methyltransferase in
human breast cancer, Eur J Cancer, 13:
961-966.
Axelrod, J. (1957) The O-methylation of
epinephrine and other catechols in vitro
and in vivo., Science, 126: 157-160.
Axelrod, J. and LaRoche, M.-J. (1959)
Inhibitor of O-methylation of epinephrine
and norepinephrine in vitro and in vivo,
Science, 130: 800-801.
Axelrod, J. and Tomchick, R. (1958)
Enzymatic O-methylation of epinephrine
and other catechols, J Biol Chem, 233:
702-705.
Bäckström, R., Honkanen, E., Pippuri, A.,
Kairisalo, P., Pystynen, J., Heinola, K.,
Nissinen, E., Linden, I.-B., Männistö, P.,
Kaakkola, S. and Pohto, P. (1989)
Synthesis of some novel potent and
selective catechol O-methyltransferase
inhibitors, J Med Chem, 32: 841-846.
Bakke, J. and Laurence, N. (1965) Effect of
dinitrophenol on pituitary-thyroid activity
in the rat, Endocrinology, 77: 382-389.
Bakke, O.M. (1970) O-methylation of
simple phenols in the rat, Acta Pharmacol
Toxicol, 28: 28-38.
Balazs, T., Murray, T.K., McLaughlin, J.M.
and Grice, H.C. (1961) Hepatic tests in
toxicity studies on rats, Toxicol Appl
Pharmacol, 3: 71-79.
Baldessarini, R.J. and Greiner, E. (1973)
Inhibition of catechol-O-methyl
transferase by catechols and polyphenols,
References
60
Biochem Pharmacol, 22: 247-256.
Barnes, X. (1969) Toxic substances and the
nervous system, Scientific basis of
Medicine: Annual reviews (British
postgraduate medical federation), Vol. 11,
Humanities Press, New York, pp. 183-
201.
Bartholini, G. and Pletscher, A. (1975)
Decarboxylase inhibitors, Pharmacol
Therap B, 1: 407-421.
Batt, A.-M. and Ferari, L. (1995)
Manifestations of chemically induced liver
damage, Clin Chem, 41: 1882-1887.
Beck, S., Hubble, J. and Reinikainen, K.
(2002) Entacapone-induced hepato-
toxicity and hepatic dysfunction, Mov
Disord, 17: 1397-1399.
Belleau, B. and Burba, J. (1961) Tropolones:
a unique class of potent non-competitive
inhibitors of S-adenosylmethionine-
catechol methyltransferase by tropolones,
Biophys Acta, 54: 195-196.
Belleau, B. and Burba, J. (1963) Occupancy
of adrenergic receptors and inhibtion of
catechol-O-methyl-transferase by
tropolones, J Med Chem, 6: 755-759.
Benichou, C. (1990) Standardization of
definitions and criteria of causality
assessment of adverse drug reactions, Int J
Clin Pharmacol Ther Toxicol, 28: 317-
322.
Berg, J.M., Tymoczko, L. and Stryer, L.
(2002) Biochemistry, Freeman and
Company, New York.
Bidstrup, P.L. and Payne, D.J.H. (1951)
Poisoning by dinitro-ortho-cresol, BMJ,
2: 16-19.
Birkmayer, W. and Hornykiewicz, O. (1961)
Der L-3,4-dioxyphenylalanin (=DOPA)-
effekt bei der Parkinson-akinese, Wiener
Klin Wochenschr, 73: 787-788.
Bonifacio, M.J., Archer, M., Rodrigues, M.L.,
Matias, P.M., Learmonth, D.A., Carrondo,
M.A. and Soares-Da-Silva, P. (2002)
Kinetics and crystal structure of catechol-
O-methyltransferase complex with co-
substrate and a novel inhibitor with
potential therapeutic application, Mol
Pharmacol, 62: 795-805.
Bonifati, V. and Meco, G. (1999) New,
selective catechol-O-methyltransferase
inhibitors as therapeutic agents in
parkinson’s disease, Pharmacol Ther, 81:
1-36.
Borchardt, R.T., Cheng, C.F., Cooke, P.H.
and Creveling, C.R. (1974) The
purification and kinetic properties of liver
microsomal catechol-O-methyltransferase,
Life Sci, 14:.
Borgulya, J., Da Prada, M., Dingemanse, J.,
Scherschlicht, R., Schläppi, B. and
Zurcher, G. (1991) Ro 40-7592.
Catechol-O-methyltransferase (COMT)
inhibitor, Drugs Future, 16: 719-721.
Borgylua, J., Bryderer, H., Bernauer, K.,
Zurcher, G. and Da Prada, M. (1989)
Catechol-O-methyltransferase-inhibiting
pyrocatechol derivatives - synthesis and
structure activity studies, Helv Chim Acta,
72: 952-968.
Borroni, E., Beck, J., Cesura, A.M., Schmitt,
M. and Gatti, S. (1999) Tolcapone and
mitochondrial function: Evidence for a
large safety margin in vitro and in vivo,
Parkinson Relat Disord, 5: S68.
Borroni, E., Cesura, A.M., Gatti, S. and
Gasser, R. (2001) A preclinical re-
evaluation of the safety profile of
tolcapone, Funct Neurol, 16 (Suppl.):
125-134.
Broch, O.J.J. (1972) The in vivo effect of
tropolone on dopamine metabolism and
the catechol-O-methyl transferase activity
in the striatum of the rat, Acta Pharmacol
Toxicol, 31: 217-225.
References
61
Brown, G.C. (1992) Control of respiration
and ATP synthesis in mammalian
mitochondria and cells, Biochem J, 284:
1-13.
Buffa, P., Guarriera-Bobyleva, V., Muscatello,
U. and Pasquali-Ronchetti, I. (1970)
Conformational changes of mitochondria
associated with uncoupling of oxidative
phosphorylation in vivo and in vitro,
Nature, 226: 272-274.
Carter, A. and Muller, R. (1990) Application
and validation of an ion-exchange high-
performance liquid chromatographic
method for measuring adenine
nucleotides, creatine and creatine
phosphate in mouse brain, J Chromatogr,
527: 31-39.
Cederbaum, J.M., Leger, G. and Guttman,
M. (1991) Reduction of circulating 3-O-
methyldopa by inhibition of catechol-O-
methyltransferase with OR-611 and OR-
462 in cynomolgus monkeys: implications
for the treatment of Parkinson’s disease,
Clin Neuropharmacol, 14: 330-342.
Chance, B. and Williams, G.R. (1955)
Respiratory enzymes in oxidative
phosphorylation, J Biol Chem, 217: 409-
427.
Chance, B. and Williams, G.R. (1956) The
respiratory chain and oxidative
phosphorylation, Adv Enzymol, 17: 65-
134.
Collan, Y. and Salmenperä, M. (1976)
Electron microscopy of postmortem
autolysis of rat muscle tissue, Acta
Neuropathol (Berl), 35: 219-233.
Colossimo, C. (1999) The rise and fall of
tolcapone, J Neurol, 246: 880-882.
Conyers, R.A.J., Hensley, W.J. and
Montague, M.D. (1968) The effect of
pyrogallol on oxidative phosphorylation,
Arch Int Pharmacodyn, 171: 179-184.
Council of Europe (1990) European
Convention for the protection of vertebrate
animals used for experimental and other
scientific purposes (ETS 123), Council of
Europe, Appendices A and B, 1991.
Cox, B. and Tha, S. (1975) The role of
dopamine and noradrenaline in
temperature control of normal and
reserpine-pretreated mice, J Pharm
Pharmacol, 27: 242-247.
Cutting, W. and Tainter, M. (1933)
Metabolic actions of dinitrophenols with
the use of balanced and unbalanced diets,
JAMA, 27: 2099-2102.
Da Prada, M., Zurcher, G., Kettler, R.,
Dingemanse, J., Jorga, K. and Dubuis, R.
(1993) Remodelling the kinetics and
dynamics of levodopa therapy in
Parkinson’s disease by inhibiting MAO-B
with lazabemide and COMT with
tolcapone. In: W. Poewe and A.J. Lees
(Eds.), Levodopa: The first 25 years,
Editions Roche, Basel, Switzerland, pp.
99-117.
Dagani, F., Ferrari, R., Anderson, J. and
Chase, T. (1991) L-Dopa does not affect
electron transfer chain enzymes and
respiration of rat muscle mitochondria,
Mov Disord, 6: 315-319.
De Santi, C., Giulianotti, P.C., Pietrabissa,
A., Mosca, F. and Pacifici, G.M. (1998)
Catechol-O-methyltransferase: variation in
enzyme activity and inhibition by
entacapone and tolcapone, Eur J Clin
Pharmacol, 54: 215-219.
Deleu, D., Northway, M.G. and Hanssens,
Y. (2002) Clinical pharmacokinetic and
pharmacodynamic properties of drugs
used in the treatment of Parkinson’s
disease, Clin Pharmacokinet, 41: 261-309.
DiMauro, S., Bonilla, E., Zeviani, M.,
Nakagawa, M. and DeVivo, D.C. (1985)
Mitochondrial myopathies, Ann Neurol,
17: 521-538.
References
62
Dingemanse, J. (1997) Catechol-O-
methyltransferase inhibitors: clinical
potential in the treatment of Parkinson’s
disease, Drug Dev Res, 42: 1-25.
Dingemanse, J., Jorga, K., Zurcher, G.,
Schmitt, M., Sedek, G., Da Prada, M. and
Van Brummelen, P. (1995) Pharmaco-
kinetic-pharmacodynamic interaction
between the COMT inhibitor tolcapone
and single-dose levodopa, Br J Pharmacol,
40: 253-262.
Dixon, M.F., Fulker, M.J., Waalker, B.E.,
Kelleher, J. and Losowsky, M.S. (1975)
Serum transaminase levels after
experimental paracetamol-induced
hepatic necrosis, Gut, 16: 800-807.
Dorris, R.L. and Dill, R.E. (1977)
Inhibition of catechol-O-methyltransferase
by N-butyl gallate, Neuropharmacology,
16: 631-634.
Dossing, M. and Sonne, J. (1993) Drug-
induced hepatic disorders, Drug Saf, 9:
441-449.
Eckhardt, K., Fukatsu, N., Hayashi, M. and
Horii, I. (1996) Embryotoxicicity study
in rats with oral administration of
tolcapone, Jpn Pharmacol Ther, 24: 123-
139.
Ellingson, T., Duddempudi, S., Greenberg,
B.D., Hooper, D. and Eisenhofer, G.
(1999) Determination of differential
activities of soluble and membrane-bound
catechol-O-methyltransferase in tissues
and erythrocytes, J Chromatogr B, 729:
347-353.
Entacapone Product Monograph (1999)
Comtess, entacapone - A COMT inhibitor
for treatment of Parkinson’s Disease. A
Product Monograph.
Ericsson, A.D. (1971) Potentiation of the L-
dopa effect in man by the use of catechol-
O-methyltransferase inhibitors, J Neurol
Sci, 14: 193-197.
European Medicines Evaluation Agency
(1998) Recommendation for the
suspension of the marketing authorisation
for Tasmar (tolcapone), Press release,
London.
Fahn, S. (1974) On-off phenomenon with
levodopa therapy in parkinsonism,
Neurology, 24: 431-441.
Fahn, S. (1998) Tolcapone: COMT
inhibition for the treatment of Parkinson’s
disease, Neurology, 50 (Suppl): S1-S2.
Fahn, S., Comi, R., Snider, R.S. and Prasad,
A.L.N. (1979) Effect of a catechol-O-
methyl transferase inhibitor, U-0521,
with levodopa administration, Biochem
Pharmacol, 28: 1221-1225.
Faunt, J. and Crocker, A. (1987) The effects
of selective dopamine receptor agonists
and antagonists on body temperature in
rats, Eur J Pharmacol, 133: 243-247.
Faupel, R., Seitz, H., Tarnowski, W.,
Thiemann, V., and Weiss, C. (1972) The
problem of tissue sampling from
experimental animals with respect of
freezing technique, anoxia, stress and
narcosis. A new method for sampling rat
liver tissue and the physiological values of
glycolytic intermediates and related
compounds, Arch Biochem Biophys, 148:
509-522.
Fisher, A., Croft-Baker, J., Davis, M., Purcell,
P. and McLean, A. (2002) Entacapone-
induced hepatotoxicity and hepatic
dysfunction, Mov Disord, 17: 1362-
1365.
Foldes, A. and Meek, J.L. (1974) Occurrence
and localization of brain phenol-
sulphotransferase, J Neurochem, 23: 303-
307.
Fountoulakis, M., de Vera, M.-C., Crameri,
F., Boess, F., Gasser, R., Albertini, S. and
Suter, L. (2002) Modulation of gene and
protein expression by carbon tetrachloride
References
63
in the rat liver, Toxicol Appl Pharmacol,
183: 71-80.
Fromenty, B., Fisch, C., Berson, A.,
Letterton, P., Larrey, D. and Pessayre, D.
(1990) Dual effect of amiodarone on
mitochondrial respiration. Initial
protonophoric uncoupling effect followed
by inhibition of the respiratory chain at
the levels of complex I and complex II, J
Pharmacol Exp Ther, 255: 1377-1384.
Garrido, J.M., Mena, M.A., Correa, C.,
Herreras, O., Jorge, P., Leenders, N.,
Antonini, A., Gunther, I., Psylla, M. and
de Yebenes, J.G. (1994) Side effects of the
catechol-O-methyltransferase inhibitor Ro
40-7592 in rabbits, Clin Neuro-
pharmacol, 17: 270-276.
Gasser, R. and Smit, R. (2001) Predictor
analysis of liver enzyme abnormalities in
association with Tasmar® (tolcapone)
treatment, Parkinson Relat Disord, 7
(Suppl): S57.
Gogos, J.A., Morgan, M., Luine, V., Santha,
M., Ogawa, S., Pfaff, D. and Karayiorgou,
M. (1998) Catechol-O-methyltransferase-
deficient mice exhibit sexually dimorphic
changes in catecholamine levels and
behaviour., Proc Natl Acad Sci, 95: 9991-
9996.
Gracey, J. (1981) Rigor mortis, Thornton’s
meat hygiene, Bailliere Tindall, London,
pp. 40-41.
Greaves, P. (1990) Histopathology of
preclinical toxicity studies, Elsevier Science
Publishers B.V., Amsterdam, pp. 403-
406.
Grossman, M., Creveling, C., Rybczynski,
R., Braverman, M., Isersky, C. and
Breaefiel, X. (1985) Soluble and
particulate forms of rat catechol-O-
methyltransferase distinguished by gel
electrophoresis and immune fixation, J
Neurochem, 44: 421-432.
Gugler, R. and Dengler, H.J. (1973)
Inhibition of human liver catechol-O-
methyltransferase by flavonoids, Naunyn
Schmiedebergs Arch Pharmacol Exp
Pathol, 276: 223-233.
Guldberg, H. and Marsden, C. (1975)
Catechol-O-methyl transferase: Pharma-
cological aspects and physiological role,
Pharmacol Rev, 27: 135-206.
Hackenbrock, C.R. (1966) Ultrastructural
bases for metabolically linked mechanical
activity in mitochondria, J Cell Biol, 30:
269-297.
Handley, S.L. and Mithani, S. (1984) Effects
of alpha-adrenoreceptor agonists and
antagonists in a maze-exploration model
of ‘fear’-motivated behaviour, Naunyn
Schmiedebergs Arch Pharmacol, 327: 1-
5.
Harman, A.W., Mahar, S.O., Burcham, P.C.
and Madsen, B.W. (1992) Level of
cytosolic free calcium during
acetaminophen toxicity in mouse
hepatocytes, Mol Pharmacol, 41: 665-
670.
Haschek, W., Rousseaux, C. and Wallig, M.A.
(2002) Handbook of Toxicologic
Pathology, Vol. 2, Academic Press, San
Diego.
Hoffman, A.R., Paul, s.M. and Axelrod, J.
(1979) Catecholestrogen synthesis and
metabolism by human breast tumors,
Cancer Res, 39: 4584-4587.
Hong, J., Shu-Leong, H., Tao, X. and Lap-
Ping, Y. (1998) Distribution of catechol-
O-methyltransferase expression in human
central nervous system, Neuroreport, 9:
2861-2864.
Horner, W. (1942) Dinitrophenol and its
relation to formation of cataract, Arch
Ophthalmol, 27: 1097-1121.
Huotari, M., Gogos, J., Karayiorgou, M.,
Koponen, O., Forsberg, M., Raasmaja, A.,
References
64
Hyttinen, J. and Männistö, P.T. (2002)
Brain catecholamine metabolism in
catechol-O-methyltransferase (COMT)-
deficient mice, Eur J Neurosci, 15: 246-
256.
Illi, A., Sundberg, S., Koulu, M., Scheinin,
M., Heinävaara, S. and Gordin, A. (1994)
COMT inhibition by high-dose
entacapone does not affect hemodynamics
but changes catecholamine metabolism in
healthy volunteers at rest and during
exercise, Int J Clin Pharm Ther, 32: 582-
588.
Inamori, Y., Tsujibo, H., Ohishi, H., Ishii,
F., Mizugaki, M., Aso, H. and Ishida, N.
(1993) Cytotoxic effect of hinokitiol and
tropolone on the growth of mammalian
cells and on blastogenesis of mouse splenic
T cells, Biol Pharm Bull, 16: 521-523.
Jeffery, D.R. and Roth, J.A. (1984)
Characterization of membrane-bound and
soluble catechol-O-methyltransferase from
human frontal cortex, J Neurochem, 42:
826-832.
Johnston, J.P. (1968) Some observations
upon a new inhibitor of monoamine
oxidase in brain tissue, Biochem
Pharmacol, 17: 1285-1297.
Kaakkola, S. (2000) Clinical pharmacology,
therapeutic use and potential of COMT
inhibitors in Parkinson’s disease., Drugs,
59: 1233-1250.
Kaakkola, S., Gordin, A. and Männistö, P.T.
(1994) General properties and clinical
possibilities of new selective inhibitors of
catechol-O-methyltransferase, Gen
Pharmacol, 25:.
Kaakkola, S. and Wurtman, R.J. (1993)
Effects of catechol-O-methyltransferase
inhibitors and L-3,4-dihydroxy-
phenylalaninen with or without carbidopa
on extracellular dopamine in rat striatum,
J Neurochem, 60: 137-144.
Kaiser, J. (1964) Studies on the toxicity of
diisophenol (2,6-diiodo-4-nitrophenol) to
dogs and rodents plus some comparison
with 2,4-dinitrophenol, Toxicol Appl
Pharmacol, 6: 232-244.
Kalaria, R.N. and Harik, S.I. (1987) Blood-
brain barrier monamine ozidase: enzyme
characterization in cerebral microvessels
and other tissues from six mammalian
species, including human, J Neurochem,
49: 856-864.
Kauppinen, R. and Hassinen, I. (1984)
Monitoring of mitochondrial membrane
potential in isolated perfused rat heart, Am
J Physiol 247: H508-H516.
Kaplowitz, N. (2001) Causality assessment
versus guilt-by-association in drug
hepatotoxicity, Hepatology, 33: 308-310.
Karhunen, T., Tilgmann, C., Ulmanen, I.,
Julkunen, I. and Panula, P. (1994)
Distribution of catechol-O-methyl-
transferase enzyme in rat tissues, J
Histochem Cytochem, 42: 1079-1090.
Kawahara, H., Houdou, S. and Inoue, T.
(1991) Scanning electron microscopic
observations on muscle cells of
experimental mitochondrial myopathy
produced by 2,4-dinitrophenol, J
Submicrosc Cytol Path, 23: 397-403.
Keller, H.H., Keller, G. and DaParada, M.
81987) Short-acting novel MAO-
inhibitors: In vitro evidence for the
reversibility of MAO inhibition of soluble
catechol-O-methyltransferase and single-
dose pharmacokinetics after oral and
intravenous administration of entacapone,
Eur J Clin Pharmacol, 46: 151-157.
Keränen, T., Gordin, A., Karlsson, M.,
Korpela, K., Pentikäinen, P.J., Rita, H.,
Schultzt, E., Seppälä, E. and Wikberg, T.
(1994) Inhibition of soluble catechol-O-
methyltransferase and single-dose
pharmacokinetics after oral and
References
65
intravenous administration of entacapone,
Eur J Clin Pharmacol, 46: 151-157.
Kobayashi, M., Takatori, T., Nakajima, M.,
Saka, K., Iwase, H., Nagao, M., Niijima,
H. and Matsuda, Y. (1999) Does the
sequence of onset of rigor mortis depend
on the proportion of muscle fibre types
and on intra-muscular glycogen content?,
Int J Legal Med, 112: 167-171.
Kopin, I. (1985) Catecholamine metabolism:
basic aspects and clinical significance,
Pharmacol Rev, 37: 333-364.
Kopin, I.J. (1994) Monoamine oxidase and
catecholamine metabolism, J Neural
Transm, 41 (Suppl): 57-67.
Koulu, M., Scheinin, M., Kaarttinen, A.,
Kallio, J. and Pyykkö, K. (1989)
Inhibition of monoamine oxidase by
moclobemide: effects on monoamine
metabolism and secretion of anterior
pituitary hormones and cortisol in healthy
volunteers, Br J Clin Pharmacol, 27: 243-
255.
Krähenbuhl, S. (2001) Mitochondria:
important target for drug toxicity?, J
Hepatol, 34: 334-336.
Kurth, M.C., Adler, C.H., St.Hilaire, M.,
Singer, C., Waters, C., LeWitt, P., Chernik,
D.A., Dorflinger, E.E. and Yoo, K. (1997)
Tolcapone improves motor function and
reduces levodopa requirement in patients
with Parkinson’s disese experiencing motor
fluctuations: A multicenter, double-blind,
randomized, placebo-controlled trial,
Neurology, 48: 81-87.
Kuruma, I., Bartholini, G., Tissot, R. and
Pletscher, A. (1971) The metabolism of
L-3-O-methyldopa, a precursor dopa in
man, Clin Pharmacol Ther, 12: 678-682.
Lasser, K.E., D, A.P., Woolhandler, S.J.,
Himmelstein, D.U., Wolfe, S.M. and Bor,
D.H. (2002) Timing of new black box
warnings and withdrawals for prescription
medications, JAMA, 287: 2215-2220.
Lattimore, J. (1934) Dinitrophenol
poisoning, Kans Med, 35: 388.
Lee, W.M. (1995) Drug-induced hepato-
toxicity, N Engl J Med, 333: 1118-1127.
Li, Y.-H., Wirth, T., Huotari, M., Laitinen,
K., MacDonald, E. and Männistö, P.T.
(1998) No change of brain extracellular
catecholamine levels after acute catechol-
O-methyltransferase inhibition: a
microdialysis study in anaesthetized rats,
Eur J Pharmacol, 356: 127-137.
Loeb, W. and Quimby, F. (1999) The clinical
chemistry of laboratory animals, Pergamon
Press, Oxford.
Loomis, W.F. and Lipmann, F. (1948)
Reversible inhibition of the coupling
between phosphorylation and oxidation,
J Biol Chem, 173: 807.
Lotta, T., Vidgren, J., Tilgmann, C.,
Ulmanen, I., Melén, K., Julkunen, I. and
Taskinen, J. (1995) Kinetics on human
soluble and membrane-bound catechol-
O-methyltransferase: a revised mechanism
and description of the thermolabile variant
of the enzyme, Biochemistry, 34: 4202-
4210.
Lowry, O., Rosebrough, N., Farr, A., and
Randall, R. (1951) Protein measurement
with the Folin reagent, J Biol Chem, 193:
265-271.
Maitre, L. (1966) Effects of long-term
administration of pyrogallol on tissue
catecholamine levels, monoamine oxidase
and catechol-O-methyltransferase activites
in the rat, Biochem Pharmacol, 15: 1935-
1946.
Männistö, P.T. (1994) Clinical potential of
catechol-O-methyltransferase (COMT)
inhibitors as adjuvants in Parkinson’s
disease, CNS Drugs, 1: 172-179.
Männistö, P.T. and Kaakkola, S. (1990)
Rationale for selective COMT inhibitors
References
66
as adjuncts in the treatment of Parkinson’s
disease, Pharmacol Toxicol, 66: 317-323.
Männistö, P.T. and Kaakkola, S. (1999)
Catechol-O-methyltransferase (COMT):
Biochemistry, molecular biology,
pharmacology, and clinical efficacy of the
new selective COMT inhibitors,
Pharmacol Rev, 51: 593-628.
Männistö, P.T., Tuomainen, P. and Tuominen,
R.K. (1992a) Different in vivo properties
of three new inhibitors of catechol-O-
methyltransferase in the rat, Br J
Pharmacol, 105: 569-574.
Männistö, P.T., Ulmanen, I., Lundström, K.,
Taskinen, J., Tenhunen, J., Tilgmann, C.
and Kaakkola, S. (1992b) Characteristics
of catechol-O-methyltransferase (COMT)
and properties of selective COMT
inhibitors, Prog Drug Res, 39: 291-350.
Masserman, J.H. and Goldsmith, H. (1934)
Dinitrophenol: Its therapeutic and toxic
actions of certain types of psychobiologic
underactivity, JAMA, 102: 523-525.
Mayoral, W., Lewis, J.H. and Zimmerman,
H. (1999) Drug-induced liver disease,
Curr Opin Gastroenterol, 15: 208-216.
McCaul, T.F., Fagan, E.A., Tovey, G.,
Portman, B., Williams, R and J, Z.A.
(1986) Fulminant hepatitis. An
ultrastructural study., J Hepatol, 2: 276-
290.
Mehendale, H.M., Roth, R.A., Gandolfi,
A.J., Klaunig, J.E., Lemasters, J.J. and
Curtis, L.R. (1994) Novel mechanisms in
chemically induced hepatotoxicity, FASEB
J, 8: 1285-1295.
Melmed, C., Karpati, G. and Carpenter, S.
(1975) Experimental mitochondrial
myopathy produced by in vivo uncoupling
of oxidative phosphorylation, J Neurol Sci,
26: 305-318.
Mizrahi, S., Dolberg, L. and Jacobsohn, W.Z.
(1987) Alteration in aminotransferase
levels in rats after acute hepatic injury, Isr
J Med Sci, 23: 188-192.
Nakagawa, Y. and Tayama, K. (1998)
Mechanism of mitochondrial dysfunction
and cytotoxicity induced by tropolones in
isolated rat hepatocytes, Chem Biol
Interact, 116: 45-60.
Nakagawa, Y. and Tayama, S. (1995)
Cytotoxicity of propylgallate and related
compounds in rat hepatocytes, Arch
Toxicol, 69: 204-208.
National Research Council (1996) Guide for
the care and use of laboratory animals,
Institute of Laboratory Animal Resources,
Commission on Life Sciences, National
Research Council.
Nissinen, E., Kaheinen, P., Penttilä, K.,
Kaivola, J. and Lindén, I.-B. (1997)
Entacapone, a novel catechol-O-methyl
transferase inhibitor of Parkinson’s disease,
does not impair mitochondrial energy
production, Eur J Pharmacol, 340: 287-
294.
Nissinen, E., Linden, I.-B., Schultz, E.,
Kaakkola, S., Männistö, P.T. and Pohto, P.
(1988) Inhibition of catechol-O-
methyltransferase activity by two novel
disubstituted catechols in the rat, Eur J
Pharmacol, 153: 263-269.
Nissinen, E., Lindén, I.-B., Schultz, E. and
Pohto, P. (1992) Biochemical and
pharmacological properties of a
peripherally acting catechol-O-methyl-
transferase inhibitor Entacapone, Naunyn
Schmiedebergs Arch Pharmacol, 346: 262-
266.
Nissinen, E., Tuominen, R., Perhoniemi, V.
and Kaakkola, S. (1988) Catechol-O-
methyltransferase activity in human and
rat small intestine, Life Sci, 42: 2609-
2614.
Nutt, J.G. and Fellman, J.H. (1984)
Pharmacokinetics of levodopa, Clin
References
67
Neuropharmacol, 7: 35-39.
Nutt, J.G., Woodward, W.R., Beckner,
R.M., Stone, C.K., K, B., Carter, J.H.,
Gancher, S.T., Hammerstad, J.P. and
Gordin, A. (1994) Effect of peripheral
catechol-O-methyltransferase inhibition
on the pharmacokinetics and pharmaco-
dynamics of levodopa in parkinsonian
patients, Neurology, 44: 913-919.
O’Carroll, A.M., Fowler, C.J., Phillips, J.P.,
Tobbia, I. and Tipton, K.F. (1983) The
deamination of dopamine by human brain
monoamine oxidase. Specificity for the two
enzyme forms in seven brain regions,
Naunyn Schmiedebergs Arch Pharmacol,
322: 198-202.
Olanow, C.W. (2000) Tolcapone and
hepatotoxic effects. Tasmar Advisory Panel,
Arch Neurol, 57: 263-267.
Orth, M. and Schapira, A.H.V. (2002)
Mitochondrial involvement in Parkinson’s
disease, Neurochem Int, 40: 533-541.
Parada, A., Loureiro, A.I., Vieira-Coelho,
M.A., Hainzl, D. and Soares-da-Silva, P.
(2001) BIA 3-202, a novel catechol-O-
methyltransferase inhibitor, enhances the
availability of L-DOPA to the brain and
reduces its O-methylation, Eur J Pharm,
420: 27-32.
Parker, V.H. (1973) Uncoupling of oxidative
phosphorylation by tribromoimidatzole
derivatives and fatty acids, Biochem
Pharmacol, 22: 1203-1219.
Peterson, G. (1977) A simplification of the
protein assay method of Lowry et al. which
is more generally applicable, Anal
Biochem, 83: 346-356.
Perkins, R. (1919) A study of the munitions
intoxications in France, Public Health Rep,
34: 2335-2374.
Poole, F. and Haining, R. (1934) Sudden
death from dinitrophenol poisoning:
Report of case with autopsy, JAMA, 102:
1141-1147.
Porsolt, R.D, Bertin, A., and Jalfre, M.
(1977) Behavioral despair in mice: a
primary screening test for antidepressants,
Arch Int Pharmacodyn Ther, 229: 327-
336.
Reches, A. and Fahn, S. (1984) Catechol-O-
methyltransferase and Parkinson’s disease,
Adv Neurol, 40: 171-179.
Research Triangle Institute (1995)
Toxicological profile for dintirophenols,
Atlanta, GA.
Ri, S. (1951) Pharmacological studies of
hinokitiol. I. On the toxicity and the local
action of hinokitiol, Niigata Igakkai
Zasshi, 65: 566-572.
Riederer, P., Konradi, C., Schay, V., Kienzl,
E., Birkmayer, G., Danielczyk, W., Sofic,
E. and Youdim, M.B.H. (1986)
Localization of MAO-A and MAO-B in
human brain: A step in understanding the
therapeutic action of L-deprenyl, Adv
Neurol, 45: 111-118.
Rivest, J., Barclay, L. and Suchowersky, O.
(1999) COMT inhibitors in Parkinson’s
disease, Can J Neurol Sci, 26 (Suppl. 2):
S34-S38.
Rivett, A.J., Francis, a. and Roth, J.A. (1983)
Distinct cellular localization of membrane-
bound and soluble forms of catechol-O-
methyltransferase in brain, J Neurochem,
40: 1494-1496.
Robert, T.A. (1986) The disposition and
acute toxicity of 2,4 -dinitrophenol and
its mono reduced metabolites in mouse
plasma and liver, Fed Proc, 45: 638.
Roberts, S.M., DeMott, R.P. and James, R.C.
(1997) Adrenergic modulation of
hepatotoxicity, Drug Metab Rev, 29: 329-
353.
Rojo, A., Fontan, A., Mena, M.A., Herranz,
A., Casado, S. and de Yebenes, J.G. (2001)
Tolcapone increases plasma catecholamine
References
68
levels in patiens with Parkinson’s disease,
Parkinson Relat Disord, 7: 93-96.
Ross, S.B. and Haljasmaa, O. (1964a)
Catechol-O-methyl transferase inhibitors.
In vitro inhibition of the enzyme in
mouse-brain extract, Acta Pharmacol
Toxicol, 21: 205-214.
Ross, S.B. and Haljasmaa, Ö. (1964b)
Catechol-O-methyl transferase inhibitors.
In vivo inhibition in mice, Acta Pharmacol
Toxicol, 21: 215 - 225.
Roth, J.A. (1992) Membrane-bound
catechol-O-methyltransferase: a re-
evaluation of its role in the O-methylation
of catecholamine neurotransmitters, Rev
Physiol Biochem Pharmacol, 120: 1-29.
Sahgal, V., Subramani, V., Hughes, R., Shah,
A. and Singh, H. (1979) On the
pathogenesis of mitochondrial myo-
pathies. An experimental study, Acta
Neuropathol (Berl), 46: 177-183.
Schapira, A.H.V. (1994) Evidence for
mitochondrial dysfunction in Parkinson’s
disease - a critical appraisal, Mov Disord,
9: 125-138.
Schapira, A.H.V. (2001) Causes of neuronal
death in Parkinson’s disease, Vol. 86,
Lippincott Williams & Wilkins,
Philadelphia.
Scheinin, M., Illi, A., Koulu, M. and Ojala-
Karlsson, P. (1998) Norepinephrine
metabolites in plasma as indicators of
pharmacological inhibition of monoamine
oxidase and catechol-O-methyl-
transferase., Adv Pharmacol, 42: 367-370.
Scheinin, M., Karhuvaara, S., Ojala-Karlsson,
P., Kallio, A. and Koulu, M. (1991) Plasma
3,4-dihydroxyphenylglycol (DHPG) and
3-methoxy-4-hydroxyphenylg lyco l
(MHPG) are insensitive indicators of
alpha
2
-adrenoceptor mediated regulation
of norepinephrine release in healthy
volunteers, Life Sci, 49: 75-84.
Schläppi, B., Jovanovic, D., Okada, M.,
Kobayashi, K. and Horii, I. (1996b) Six-
month oral toxicity study of tolcapone in
rats (feed admix), Jpn Pharmacol Ther, 24:
49-102.
Schläppi, B., Morimoto, H., Kobayashi, K.
and Horii, I. (1996c) Six-month oral
toxicity study with tolcapone on Beagle
dogs, Jpn Pharmacol Ther, 24 (Suppl 10):
77- 102.
Schläppi, B., Okada, M., Kobayashi, K. and
Horii, I. (1996a) Four-week oral toxicity
study of tolcapone in rats (gavage), Jpn
Pharmacol Ther, 24: 13-27.
Schwetz, B.A. and Plaa, G.L. (1969)
Catecholamine potentiation of carbon
tetrachloride-induced hepatotoxicity in
mice, Toxicol Appl Pharmacol, 14: 495-
509.
Senoh, S., Daly, J., Axelrod, J. and Witkop,
B. (1959) Enzymatic p-O-methylation by
catechol O-methyl transferase, J Am Chem
Soc, 81: 6240 - 6245.
Shah, A., Sahgal, V., Muschler, G.,
Subramani, V. and Singh, H. (1982)
Morphogenesis of the mitochondrial
alterations in muscle diseases, J Neurol Sci,
55: 25-37.
Shah, A., Sahgal, V., Sahgal, S., Subramani,
V. and Kochar, H. (1985) Mitochondrial
cytochemistry in experimental myo-
pathies, J Submicrosc Cytol, 17: 509 -
515.
Shih, J.C., Chen, K. and Ridd, M.J. (1999a)
Role of MAO A and MAO B in
neurotransimitter metabolism and
behaviour, Pol J Pharmacol, 51: 25-29.
Shih, J.C., Chen, K. and Ridd, M.J. (1999b)
Monoamine oxidase: From genes to
behavior, Annu Rev Neurosci, 22: 197-
221.
Simon, E.W. (1953) Mechanisms of
dinitrophenol toxicity, Biol Rev, 28: 453-
References
69
479.
Simpson, G.M. and Varga, V. (1972) An
investigation of the clinical effect of GPA-
1714, a catechol-O-methyl transferase
inhibitor, J Clin Pharmacol New Drugs,
10: 417-421.
Smith, L.A., Gordin, A. and Jenner, P. (1997)
Entacapone enhances levodopa-induced
reversal of motor disability in MPTP-
treated common marmosets, Br J
Pharmacol, 112: 13-18.
Spahr, L., Rubbia-Brandt , L., Burkhard, P.,
Assal, F. and Hadengue, A. (2000)
Tolcapone-related fulminant hepatitis:
Electron microscopy shows mitochondrial
alterations, Dig Dis Sci, 45: 1881-1884.
Spencer, H., Rowe, V. and Irish, D. (1948)
Toxicological studies on laboratory animals
of certain alkyldinitrophenols used in
agriculture, J Ind Hyg Toxicol, 30: 10-
25.
Stoner, H., Threlfall, C. and Green, H.
(1952) The effect of 3,5-dinitro-orto-
cresol on the organic phosphates of muscle,
Br J Exp Pathol, 33: 398-404.
Tainter, M. and Cutting, W. (1933b)
Miscellaneous actions of dinitrophenol.
Repeated administrations, antidotes, fatal
doses, antiseptic tests and actions of some
isomers, J Pharmacol Exp Ther, 49: 187-
209.
Tainter, M. and Wood, D. (1934) A case of
fatal dinitrophenol poisoning, JAMA,
102: 1147.
Tasmar Product Monograph (1997) , F.
Hoffman-La Roche Ltd, Basel, Switzer-
land.
Tenhunen, J., Heikkilä, P., Alanko, A.,
Heinonen, E., Akkila, J. and Ulmanen, I.
(1999) Soluble and membrane-bound
catechol-O-methyltransferase in normal
and malignant mammary gland, Cancer
Lett, 144: 75-84.
Tenhunen, J., Salminen, M., Lundström, K.,
Kiviluoto, T., Savolainen, R. and Ulmanen,
I. (1994) Genomic organization of the
human catechol O-methyltransferase gene
and its expression from two distinct
promoters, Eur J Pharm, 223:.
Terada, H. (1990) Uncouplers of oxidative
phosphorylation, Environ Health
Perspect, 87: 213-218.
Teräväinen, H., Rinne, U. and Gordin, A.
(2001) Catechol-O-methyltransferase
inhibitors in Parkinson’s disease, Vol. 86,
Lippincott Williams & Wilkins,
Philadelphia, 311-325 pp.
Thomas, J.A. (2002) Black box warning
labels and drug withdrawals, Tox Appl
Pharmacol, 183: 81-82.
Tilgmann, C., Melen, K., Lundström, K.,
Jalanko, A., Julkunen, I., Kalkkinen, N.
and Ulmanen, I. (1992) Expression of
recombinant soluble and membrane-
bound catechol-O-methyltransferase in
eukaryotic cells and identification of the
respective enzymes in rat brain, Eur J
Biochem, 207: 813-821.
Timm, U. and Erdin, R. (1992)
Determination of the catechol-O-
methyltransferase inhibitor Ro 40-7592
in human plasma by high-performance
liquid chromatography with colourimetric
detection, J Chromatogr, 308: 93-100.
Travlos, G.S., Morris, R.W., Elwell, M.R.,
Duke, A., Rosenblum, S. and Thompson,
M.B. (1996) Frequency and relationship
of clinical chemistry and liver and kidney
histopathology findings in 13-week
toxicity studies in rats, Toxicology, 107:
17-29.
Trounce, I., Kim, Y., Jun, A. and Wallace,
D. (1996) Assessment of mitochondrial
oxidative phosphorylation in patient
muscle biopsies, lymphoblasts, and
transmitochondrial cell lines, Methods
References
70
Enzymol, 264: 484-509.
Törnwall, M. and Männistö, P.T. (1991)
Acute toxicity of three new selective
COMT inhibitors in mice with special
emphasis on interactions with drug
increasing catecholaminergic neurotrans-
mission, Pharmacol Toxicol, 69: 64-70.
Törnwall, M. and Männistö, P.T. (1993)
Effects of three types of catechol-O-
methylation inhibitors on L-3, 4-
dihydroxyphenylalanine-induced circling
behaviour in rats, Eur J Pharmacol, 250:
77-84.
Ulmanen, I., Peränen, J., Tenhunen, J.,
Tilgmann, C., Karhunen, T., Panula, P.,
Bernasconi, L., Aubry, J.-P. and
Lundström, K. (1997) Expression and
intracellular localization of catechol O-
methyltransferase in transfected
mammalian cells, Eur J Biochem, 243:
452-459.
Vaalavirta, L., Koponen, A., Aho, P.,
Holopainen, A. Haasio, K., and Linden,
I-B (1998) Entacapone, a novel COMT
inhibitor for Parkinson’s disease does not
impair energy metabolism in the rat, Mov
Disord, 11 (Suppl 1): 162.
Waldmeier, P.C., Baumann, P.A., Feldtrauer,
J.J., Hauser, K., Bittiger, H., Bischoff, S.
and Von Sprecher, G. (1990) CGP
28014, a new inhibitor of cerebral
catechol-O-methylation with a non-
catechol structure, Naunyn Schmiede-
bergs Arch Pharmacol, 342: 305-311.
VanVleet, J.F. and Alberts, J.O. (1968)
Evaluation of liver function tests and liver
biopsy in experimental carbon
tetrachloride intoxication and extrahepatic
bile duct obstruction in the dog, Am J
Vet Res, 29: 2119-2131.
Warthin, A.S. (1918) A fatal case of toxic
jaundice caused by dinitrophenol, Bull Int
Assoc Med Mus, 7: 123-126.
Vasar, E., Peuranen, E., Ööpk, T., Harro, J.
and Männistö, P.T. (1993) Ondansetron,
an antagonist of 5-HT
3
 receptors,
antagonizes the anti-exploratory effect of
caerulein, an agonist of CCK receptors, in
the elevated plus-maze, Psycho-
pharmacology, 110: 213-218.
Watkins, P. (2000) COMT inhibitors and
liver toxicity, Neurology, 55 (Suppl 4):
S51-S52.
Weinbach, E.C., Garbus, J. and Sheffield,
H.G. (1967) Morphology of
mitochondria in the coupled, uncoupled
and recoupled states, Exp Cell Res, 46:
129-143.
Weisz, J., Fritz-Wolz, G., Gestl, S., Clawson,
G.A., Creveling, C.R., Liehr, J.G. and
Dabbs, D. (2000) Nuclear localization of
c in neoplastic and nonneoplastic
mammary epithelial cells, Am J Pathol,
156: 1841-1848.
Vieira-Coelho, M.A. and Soares-da-Silva, P.
(1999) Effects of tolcapone upon soluble
and membrane-bound brain and liver
catechol-O-methyltransferase, Brain Res,
821: 69-78.
Wikberg, T., Vuorela, A., Ottoila, P. and
Taskinen, J. (1993) Identification of major
metabolites of the catechol-O-methyl-
transferase inhibitor entacapone in rats
and humans, Drug Metab Dispos, 21: 81-
92.
Wylie, D.W., Archer, S. and Arnold, A.
(1960) Augmentation of pharmacological
properties of catecholamines by O-methyl
transferase inhibitors, J Pharmacol Exp
Ther, 130: 239-244.
Young, W.F., Laws, E.R., Sharbrough, F.W.
and Weinshilboum, R.M. (1986) Human
monoamine oxidase, Arch Gen Psychiatry,
43: 604-609
Zempel, J.A., Dietz, F.K. and Traiger, G.J.
(1983) Effect of amphetamine,
References
71
Pharmacologist, 25: 169.
Zürcher, G., Colzi, A. and Da Prada, M.
(1990a) Ro 40-7592-Inhibition of
COMT in rat brain and extracerebral
tissues., J Neural Transm, 32 (Suppl.):
375-380.
Zürcher, G., Keller, H.H., Kettler, R.,
Borgylua, J., Bonetti, E.P., Eigenmann, R.
and Da Prada, M. (1990b) Ro 40-7592,
a novel, very potent, and orally active
inhibitor of catechol-O-methyltransferase:
a pharmacological study in rats, Adv
Neurol, 53: 497-503.
References
